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Radiobiological modelling is essential to the progress of clinical radiotherapy. The use
of robust normal-tissue complication probability (NTCP) models has the potential to
allow truly individualised treatment plans where the tumour control probability is not
limited unnecessarily by the sometimes conservative application of techniques based on
the response of a population.
In this thesis NTCP models and methodsfor analysingclinical data are tested on data
simulated by a 3D mechanistic model of normal-tissue damage. This mechanistic model
was developed to represent local tissue damage by functional subunit inactivation, and
the overall organ response bya critical functioning volume (CFV). Thesize of the CFV
varies between organs and depends on the volumeeffect, i.e. how large volumesof tissue
damage are necessary to cause a complication. The model complexity was guided by the
degree of information available about the pathogenesis of radiation-induced side-effects.
The model was used to generate pseudo-clinical datasets, which typically consisted
of dose-volume histograms (DVHs) and binary complication information, for a large
numberof simulated treatments. Becauseall dataset characteristics and the ‘biology’
of the organs were known, studies on the simulated data could give insights into data
analysis methodology.
It was demonstrated that correlation analyses between dose-volume parameters and
outcomeare strongly influenced by dataset characteristics, but that information about
the volumeeffect of the organ can be gained if care is taken to identify all factors
influencing the observed correlations.
The relative performance of several DVH-based NTCP models was explored for
different levels of confounding factors, and it was found that model performance was
influenced more by confounding factors than by the choice of model.
The 3D mechanistic model of normal-tissue damage, developedin this thesis, is a
powerful tool for studying data analysis methodology andis also useful as a framework for
summarising the radiobiological knowledgebase of normal-tissue effects in radiotherapy.
There is great potential to develop the modelfurther to include e.g. non-localeffects
of irradiation, time effects, and several FSU populations, related to different endpoints,
co-existing in one organ.
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Chapter 1
Introduction
1.1 Pathogenesis of radiation side effects
Modern radiotherapy techniques generally cause no or mild side effects, although a few
patients experience serious morbidity following radiotherapy [1]. Irradiation of the heart
and spinal cord can lead to the lifethreatening condition ischaemic heart disease [2]
and paralysis [3] respectively, and poor lung function [4], rectal injury [5], dysphagia
[6, 7, 8] etc., caused by irradiation, can lead to severely reduced qualityof life. However,
treatment schedules have been developed which are associated with a low risk of such
seriousside effects [1]. This limits the radiation dose which can be delivered to the
tumour since increasing the dose to the tumour generally leads to higher doses in the
normal tissues aroundit. It is therefore important to study the tolerance of normal
tissues to irradiation in order not to limit the dose unnecessarily in patients with a low
risk of developing complications since this would decrease the chances of achieving local
tumour control.
1.1.1 Tissue damage
Like chemotherapy, radiotherapy is a cytotoxic treatment where the goal is to prevent
cell proliferation in the tumour by inducing reproductive cell death. Since also normal
tissues are unavoidably irradiated to some extent, cell dysfunction andcell death can
lead to tissue damage and organ failure. Radiation causes damage throughionisation,
which transforms molecules into unstable free radicals. DNA molecules can be damaged
directly, but 70% of the biological damage by a photon beam is caused byfree radicals,
formed from water, which react with DNA and other biological molecules [9, p. 56].
Generally cell death following radiotherapy is in the form of mitotic cell death,
i.e. the proliferative capacity of the cell is lost. However, all the irradiated cells
uninterruptedly perform their normal function throughout their normallife span [9, 10].
The mitotic process is the most radiosensitive cell function, since the chromosomesin
the cell nucleus, on whose integrity mitosis is dependent, are unique; in contrast cell
plasma components, maintaining othercell functions, generally exist in large numbers
and are easily regenerated by the cell [9, 11]. Therefore it is reasonable to assume
normalcell function after radiotherapy until cell death, even in cells that have been
irreversibly damaged [9, ch. 6]. Also, surviving cells can be assumed not to contribute to
tissue damage [12]. Damaged stem cells, however, fail to proliferate through mitosis so
that the tissue is eventually depleted of its cells. For the lung for example, this means a
manifestation of the normal-tissue effect 2 to 4 months after radiotherapy (10, 13].
Theviability of a cell after irradiation can be assessed in vitro by its colony-forming
ability [9, ch. 6]. A cell which does not retain full proliferative capacity will not
contribute to future generations of cells. The intrinsic radiosensitivity of a cell line is
often evaluated based on dose-response curves, created by counting the fraction of cells
which retain their colony-forming ability after delivering increasing doses of radiation
to groups of such cells. Tumourcells do not seem to differ from similar normal cells
in terms of intrinsic radiosensitivity; the mechanisms inducing apoptosis after damage
to vital chromosomes might not function normally in tumourcells, but cell survival
ultimately depends on the colony-forming ability, which is lost during irradiation even
if damaged cells do not disappear immediately. However, the radiation response of a
cell also depends on its environment, and in this respect there are differences between
tumourcells and normal-tissue cells (9, ch. 12].
Not all organs andtissues are built of proliferating cells, but rather mature post-
mitotic cells [13]. In some organs, though, such cells have the capacity to start pro-
liferating if necessary, and in other organs a constant renewal of the cell population
takes place, to compensate for natural cell loss. Tissues without any cell population
turnover are especially radiation resistant since no proliferative capacity is necessary.
However, the common conclusion that tissues with slow turnover are generally more
radioresistant than tissues with fast turnover is misleading [9, p. 217]; the only difference
is that serious tissue damage appearsearlier for the latter cell type, if irradiated with a
high dose. However, since tissue integrity depends on the composite effect of cell loss,
cell proliferation and cell migration, cell populations among early responding tissues
with especially short cycle might experience moresevereeffects if cell loss is much faster
than cell migration, as illustrated by Partridge [14].
Cell kill by radiation can be described mathematically with the linear-quadratic
(LQ) model [11, 15], where the surviving fraction (SF) of cells, irradiated with dose d,
is
SF =e0d6 (1.1)
Here a and £ are radiosensitivity parameters associated with dose-rate independent
and dose-rate dependentcell-killing mechanisms respectively [16]. If several (n) equal
fractions of dose d are delivered, separated by enough time to allow complete repair of
sublethal damage, and at high dose-rate so that this repair is negligible during each
treatment fraction,
SF = e~and—Bnd? _ .-and(1+a%5)_ (1.2)
The fraction a/( is related to the fractionation sensitivity of the tissue, and is around
1-5 Gy for late responding tissues and around 8-12 Gy for early respondingtissues [17].
Tumourcells generally also have a high a/(.
Since the total effect of a fractionated treatment depends onthe fraction size, doses
are often normalised to the equivalent total dose in 2-Gy fractions which, according to
the LQ model, would give the samecellkill:
 1+—%EQD?2 = nd -— = (1.3)
a/B
After normalisation, doses given in fractions of different sizes can be compared in terms
of EQD2.
This traditional framework of radiation-induced tissue damage,called the target cell
theory [{18, 19], has been criticised for being too simple [20, 21]. It is now clear that,
even in so-called late responding tissues, radiation triggers processes which develop
throughout the latent period before the manifestation of clinical symptoms. Thecellular
homeostasis is perturbed and cytokines are released, sending messages between cells,
the effect of which is highly unpredictable. Cytokines are associated with the induction
of free radicals and inflammation which can cause additional tissue damage, or indeed
protection. However, despite the recent interest in these mechanismsit is recognised
that, although direct radiation cell kill is not the only cause of radiation pathology, it is
probably the most important {22, 20, 21].
The importance of free radicals for radiation-induced tissue damage was mentioned
above. Interestingly several other pathologies are attributed to the tissue damage caused
by free radicals [23, p. 20]. Also, the normal-tissue reactions to radiation are not unique
but are observed as a result of attack by various agents [24, 21]. An importantdifference,
though, might be the repetitive nature of the injury caused by fractionated radiotherapy,
which is delivered under continually changing pathological conditions [25]. Considering
the biological events caused by irradiation it is natural to expect the normal-tissue
response to radiotherapy to be influenced by pre-existing co-morbidity as well as by other
treatment modalities such as surgery and chemotherapy [25, 13]. The clinical expression
of radiation toxicity also seems to be influenced by post-treatment pharmacological
interventions and diseases [25].
1.1.2 Organ failure
It is important to differentiate between tissue damage and morbidity [21]. In some
organs a complication occurs if any tissue damageatall is observed. This is the case for
moist desquamation in the skin and ulceration in the rectum. This kind of complication
has been named anatomical/structural organ failure [26]. In other organs, and for other
endpoints, the link between tissue damage and organfailure is less straightforward.
In some organs the function is performed “in parallel” by multiple subunits, such as
the alveoli in the lung, nephrons in the kidney and acini in the liver. This means
that with increasing tissue damagethere will be a gradual loss of organ function since
the undamaged parts of the organ are unaffected but must cope with an increasing
workload [19]. Moreover, these organs often have a functional reserve and a complication
does not occur until a significant fraction of the organ has been damaged [27].
Marks [27] also discusses the relative importanceofdifferent tissues within a given
organ. Organ failure can result from excessive damage to any essential cell population
within the organ, and perhapseven outside the organ. Thus, the complication probability
can have a complex dependence on the dose distribution. Organ dysfunction might
occur as a result of a large fraction of radiosensitive cells being damaged through the
irradiation of large volumesto relatively low doses, but if instead the irradiated volume
were limited, but small regions received very high doses, a cell population which is less
radiosensitive might be affected. Also, since similar symptomscan arise from damage to
differentcells it is often difficult to identify the pathogenesis of a given complication [26].
In manyorgans different regions contribute heterogeneously to organ function, and
even moreso if diseased. As a consequence,irradiating different parts of an organ could
have different effects. The bladder, femur, lung and kidney are examples of organs
commonly exhibiting complications from radiotherapy which have internal structures
which might lead to a heterogeneous responseto irradiation [27].
On a population basis the prescription dose is guided by the tolerance of the organs at
risk [28]. The rationale of conformal radiotherapy is that the tolerance dose of an organ
(assuming homogeneouspartial organ irradiation) often increases if the irradiated volume
decreases. This phenomenonis called the volume effect and can be caused by several
different mechanisms [1, 29]. Firstly, the dose-volume response of an organ strongly
depends onits functional reserve. If the functional reserve is large the complication
probability is associated with the overall tissue damage, whilst if it is small even small
volumes of tissue damage cause morbidity. Alber and Niisslin called this the volume
effect of the first kind [30]. Secondly, for anatomical/structural damage, tissue repair
often relies on migration of viable cells into the damaged volume, and in this case
there is a saturation of damage when distances within the damaged volume exceed the
distance over which a cell can migrate. It is therefore not surprising that the critical
irradiated volume seems to be independentof thesize of the individual [26]. Thirdly, the
stochastic nature of radiation damage can cause a volumeeffect in sometissues [1, 29]
(called the volumeeffect of the second kind by Alber and Niisslin [30]). This would
be the case if a complication were triggered by a certain amount of contiguous tissue
damage,since, if a larger volumeis irradiated the likelihood increases that, somewhere
in the organ, a critical contiguous volume is damaged. Finally, it is also possible that
the radiosensitivity of a tissue could increase with increasing irradiated volume[29],
perhaps due to secondary injury caused by oxygen radicals produced by inflammatory
cytokines (which can also cause ‘outoffield’ effects) [21]. If morecells are irradiated the
amount of cytokines in the irradiated volume could increase, leading to the additional
tissue damage, andalso a certain level of damage outside the irradiated volume[21].
Morethan oneoftheeffects listed above could be important for the responseofa single
organ. It is clear that not only cell kill, but also the architecture and physiology of the
organ at risk, are important for the risk of complications from radiotherapy (26, 21].
As an example, reducing the volumeirradiated for an organ with a small volume
effect can sometimes reduce the complication probability considerably, as pointed out by
Fenwick and Nahum [31], however, such a reduction in irradiated volume would not allow
a large increase in maximum dose. This is because the benefit of reducing the treated
volume comes from the reduced complication probability due to stochastic effects (third
mechanism mentioned above), whilst, since the volumeeffect is small, the complication
probability would increase sharply with the maximum dose(first mechanism). Generally,
however, an organ with a large volumeeffect would be expected to benefit more from
a reduction in treated volume, compared to an organ with a small volume effect, and
such a reduction in treated volume would allow an increase in dose.
1.1.3. Functional subunits
A functional subunit (FSU) is the tissue volume which can be regenerated by a single
stem cell. Consequently, if all FSUs retain at least one stem cell no tissue damage occurs
from irradiation. According to Withers et al. [29] “organ function depends upon the
aggregation of cells into functional subunits”. Each FSU performs the samefunction,
and if damaged cannot be rescued by stem cells from neighbouring FSUs.
In addition, the architecture of some tissues can be described in terms of structural
subunits which perform the tissue function independently (but might need several
surviving stem cells). Importantly, the FSU is defined for tissue repair purposes, whilst
the structural subunit is anatomically defined. In some cases the structural subunit
might be identical to the FSU, as seems to be the case for the nephron in the kidney;
on the other hand, one tubule of the testis (the structural subunit) consists of multiple
FSUs; and in some cases the FSU includesseveral structural subunits (e.g. intestinal
crypts, hair follicles) [29].
The relationship between tissue damage and organ dysfunction depends on the
organisation of the FSUsin the tissue [21]. It is sometimes helpful to compare the FSU
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Figure 1.1: Schematic illustration of a) serial and b) parallel organisation of FSUs.
to an electrical component which can be connected to other components in series or in
parallel; see figure 1.1. A serial organ architecture is characterised by FSUsorganised
in line, and the organ function is often structural which means that the loss of any one
of the FSUswill cause morbidity. In a parallel organ, on the other hand, the FSUs
contribute to organ function independently and the loss of a few FSUs does not lead
to total loss of organ function. Consequently, serial organs, like the spinal cord, have
a very small functional reserve, whilst parallel organs, like the lung, can have a large
functional reserve.
These different types of tissue architecture have also been compared to a chain and
a rope, respectively, since the rope has a certain redundancy offibers whilst the chain
dependson all links being intact [32]. However, since the structure and function of
different organs differ greatly, such analogies can only be taken so far and though the
concept of the FSU seems flexible enough to be useful in the description of most organs,
the analogy with electric circuits has severe limitations. It is probably more useful, and
less misleading, to characterise an organ in terms of the size of its functional reserve,
than as a serial/parallel organ [33].
Since by definition an FSU can be regenerated by a single surviving stem cell the
dose resulting in tissue damage depends not only on the intrinsic radiosensitivity of the
cells, but also on the numberof stem cells in an FSU [34, 21]. If the FSUs have few
stem cells they are morelikely to loose them all if irradiated, and thus it is morelikely
that some FSUswill be destroyed. In contrast, if there are many stem cells in each FSU
all FSUs might survive, in which case the tissue retains its integrity even if a lot ofcells
are killed.
As described in section 1.1.2 the function of an organ generally depends on more
than onecell population, and though one kind of FSU might include different kinds
of cells, e.g. type I and type II pneumocytes in the pulmonary epithelium, in some
cases it is more appropriate to describe the tissues of an organ in termsofdifferent
FSU populations. Such FSU-pupulations can have different architectures and functional
reserves; a typical example is the parenchyma andthe vasculature [35], or similarly
the parenchyma and the bronchial tree in the lung. If all pneumocytes of somealveoli
are killed by radiation the effect is a corresponding loss of parenchymal FSUs which
largely function independently of each other. In contrast, the structure of the bronchial
tree makes damage to large bronchi in the central lung much moredetrimental than
damage to the peripheral bronchi, since all airways downstream will be affected [36, 37].
Evidence from radiation-induced rectal injury indicates that such populations of FSUs
can be interdependent, and damage to the microvascular endothelium cause secondary
damage to the epithelial cells of the mucosa [38].
1.2 Treatment plan evaluation
Evidence-based medicine requires modelling on experimental andclinical data to guide
treatment planning, for e.g. drug or radiation prescription. Typically the data is binary:
success versusfailure of the treatment, or presence versus absenceof a treatment-induced
side-effect. There are standard statistical methods to model binary data, in terms of
the probability of causing a certain effect, given the value of a continuous variable
such as dose; see section 3.1.1. These methods are generally directly applicable when
modelling tumour control probability (TCP), since each patient can be characterised by
success/failure of the treatment for a given radiation dose prescribed to the tumour.
Underthese conditions the TCP is an s-shaped function of the prescription dose, which
can be parameterised e.g. by its slope and location on the dose axis.
In radiotherapy the treatment plan is also evaluated in terms of its normal-tissue
complication probability (NTCP). If a whole organ, or a part of an organ,is irradiated
to a uniform dose the NTCP can be modelled as an s-shaped function of the dose to the
organ, similarly to the TCP case. However, it is desirable to keep the dose to normal
tissues in the vicinity of a radiotherapy target as low as possible, without compromising
tumour control, which generally causes the three-dimensional (3D) dose distribution
in the normal tissues to be highly heterogeneous. In this case the binary outcome
(normal-tissue complication) depends, not on a single continuous dose variable, but on
a 3D distribution of dose.
Thus, a large amount of data must be considered when modelling NTCP [35], andif
standard statistical methods of modelling binary data are to be used, this problem needs
to be simplified. Conventionally, the 3D dose distribution in an organ has been reduced
to a dose-volume histogram (DVH), which summarises the dose distribution in terms of
the volumesreceiving a range of doses. Any spatial information in the treatment plan
is lost in this step.
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Figure 1.2: Three cumulative DVHsfor an organ at risk. The dotted DVHis clearly
the safest alternative since all dose levels are given to smaller volumes, but since the
full and the dashed lines cross over a visual evaluation of the DVHsis not enough to
rank one as safer than the other.
For common organs at risk (OAR) cumulative DVHsare useful as graphical evalua-
tions of treatment plans, and unless the DVHscorresponding to two treatment plans
cross over, the plan resulting in lower volumestreated to lower doses should beassociated
with a lower NTCP;see figure 1.2. However, DVHsarestill too complex for standard
statistical modelling, and are often summarised by single DVH metrics such as the mean
dose, maximum dose, V, (the volumereceiving at least x Gy) and D, (the lowest dose
to the hottest 7% of the OAR). Other metrics often used to summarise the DVH are
an effective volume (Veg) and an equivalent uniform dose (EUD), which, according to
some function, reduce the DVHto a single value but are derived from the full DVH; see
section 2.1.1.
1.3. Aims
As discussed in section 2.2, the risk of causing radiation-inducedside-effects can be
quantified based on direct statistical analyses of collected clinical and dosimetric data,
or by the application of a conceptual risk model to the treatment plan. The former
approach involves limitations of generality since it is based on observed outcomesin a
limited clinical context, and for the second approachto bereliable all radiobiological
assumptions in the model must bevalid.
One way of evaluating the generality of conclusions from a clinical study or the
validity of a conceptual modelis to perform animal studies where different confounding
factors can be controlled and untried dose distributions can be applied to normaltissues
without concern for the risk of complications. Examples of the contribution of animal
models to current understanding of organ response to irradiation are the studies of the
spinal cord volumeeffect, and the studies of the spatial variability of tissue response in
the lung, performed on mice and rats [39, 40, 41].
This thesis introduces an alternative method of exploring the interface between
theoretical radiobiology and clinical radiotherapy. A mechanistic 3D computer model
of an organ/normaltissue is developed, with local tissue damage represented by FSU
inactivation. The volume effect (determining organ injury) is represented by a variable
“critical functioning (fractional) volume” (CFV). Unlike DVH-based NTCP models, this
model can includespatial effects of dose distributions, and rather than to evaluate treat-
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ment plans its purposeis to simulate radiotherapy treatments, generating pseudo-clinical
complication data for a patient depending on the choice of a set of parameters. Large
numbers of treatments can be simulated in order to test data analysis methodologies.
The model can also be a tool for investigating the behaviour of existing NTCP models
for arbitrary dose distributions.
The model is described in detail in chapter 4, as well as the methods of choosing
parameter values and generating dose distributions. In chapter 5 clinical datasets
are simulated for hypothetical organs in order to explore the influence of dataset
characteristics on correlations between dose-volume parameters and outcome.
Further, in chapter 6 the parameter values of the 3D model are adapted to simulate
two real organs, lung and rectum,as closely as possible, and the radiobiological knowledge
base necessary for mechanistic modelling is explored. After having tuned the model
parameters to these organs, in chapter 7 clinical datasets are again simulated in order
to compare the performanceof different DVH-based NTCP models for different levels
on inter-patient variation in radiosensitivity and health status.
The 3D modelis developed as a biological mechanistic model, aiming to represent
the mechanisms of normal-tissue damage. The level of complexity has been guided
by the degree of information available about the pathogenesis of radiation-induced
side-effects, by a principle of generality which allows it to be applied to different organs,
and at the sametime a desire to accommodate organ specific features of anatomy and
physiology which influence the organ responseto irradiation [26]. One aim of this work
is to gain further understanding of the factors influencing the risk of radiation-induced
morbidity, by adjusting the parameter values to experimental andclinical findings and
comparing the resulting simulations with clinical studies. Thus, like other attempts to
model normal-tissue effects mechanistically, this work aims to give a glimpse into the
black box of radiotherapy.
The nature of the model output, as a binary response, makes the model especially
suitable for simulating clinical data rather than for treatment plan evaluation (although
treatment plan evaluation would be possible through averaging over patient variability).
Therefore most of this work focuses on generating representative clinical datasets which
are not limited in terms of numbers, treatment technique or even complication rate, in
contrast to real clinical data. Since the 3D modelis unlikely to be a perfect representation
11
of the normal-tissue response, such results do not so much predict the normal-tissue
response under such unexplored conditions, as provide a tool for testing data analysis
methodology. Little is known about how the measures currently used in treatment plan
evaluation relate to the biology of the individual being treated or the population which
these measures are taken from. By applying data analysis methods to datasets where
the ‘biology’ is known the link to population statistics is explored.
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Chapter 2
Normal-Tissue Complication
Probability Models
2.1 DVH-based NTCP models
DVH metrics are often used as constraints in treatment planning and they can be
linked to NTCP byfitting s-shaped functions to clinical data. There is a growing
interest in the clinical application of such models, especially in combination with a DVH
reduction scheme which takes the doses to all volumes into account. Most DVH-based
NTCP models which are suitable for clinical use reduce the DVH to a single summary
measure under some assumptions of an organ-specific volumeeffect, reasoning that the
architecture of an organ can make it especially vulnerable to specific features of a dose
distribution. Moreover, DVH reduction schemes implicitly or explicitly assume a local
dose effect mechanism. For example, if a tissue were believed to be destroyed above a
threshold dose, x Gy, but spared for doses below this threshold, a step function would
be adopted for the DVH reduction and the DVH metric of importance would be V; (the
volumereceiving at least z Gy). Similarly, if the mean organ dose is chosen as summary
measure, the effect on the tissue is assumed to increase linearly with increasing dose.
Alber [42] showed that treatment plan optimisation can be based on minimising the
summary measure of choice, without having to calculate NT'CP. However,it is often
useful to link the summary measureto an actual risk estimate.
Generally one or two parameters are used in the DVH reduction expression. The
resulting summary measureis then related to the NIT'CP with an s-shaped function
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which uses two additional parameters, e.g. the value of the summary measureresulting
in 50% complication probability and the slope of the curve at this point [43, 44]. The
most common s-shaped functions for modelling binary data are the logit and the probit
(cumulative normal) functions {45, ch. 3], whilst in NTCP modelling also an exponential
binomial or Poisson function is often used [46, 20, 47], since this provides a direct link to
radiation cell kill through the LQ model [15]. As reviewed by Bentzen and Tucker, it has
been suggested that the exponential function is a superior choice due to its mechanistic
aspect [48], whilst the advantage of the logit function is its computational simplicity
[49, 45]. Moreover, the latter provides a natural methodof incorporating non-dosimetric
predictors; see section 7.2.3. However, the most commonly used NT'CP model, the
Lyman-Kutcher-Burman (LKB) model [50, 51] uses the probit function. The probit
function has a connection to radiobiology since it approximates the cumulative binomial
function which has been used to model the probability of damaging an FSU [52]; see
section 2.2.
For a chosen summary measure, ¢, the probit function gives the NTCP:
 
1 tNTCP = — —2/24 2.1
V 20 [.. : * ( )
where
? — $50t= ; 2.2m + b50 cp
Here, the value of ¢ associated with 50% NTCP, 50, and therelative standard deviation,
m, are two parameters whicharefitted to clinical data. As pointed out by Tsougos et
al. [53], this model assumes a normally distributed probability distribution for ¢59, and
the slope of the curve (and thus m) dependson its variance. The s-shaped curve given
by this function is illustrated in figure 2.1.
Someof the local dose effect measures most commonly used in equation 2.2 are
summarised below (section 2.1.1 and 2.1.2). It is the assumptions about the volume
effect and local dose effect mechanisms whichdiffer between the models. A commonly
used model with a ‘reversed’ structure is the relative seriality model (section 2.1.3).
With this model dosesarefirst translated to probabilities, and then a probability-volume
histogram is reduced to an NTCP, based on assumptions about the volumeeffect.
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Figure 2.1: Illustration of the s-shaped curve given by the probit function with mean
59 and relative standard deviation m.
In the presentations which follow, it is assumed that all doses have been normalised
with respect to fraction size and expressed as EQD2, as described in section 1.3.
2.1.1 The LKB model
The DVHis most often reduced to the dose which would cause the same NTCPif given
uniformly to the whole organ, the equivalent uniform dose (EUD). Different expressions
for the EUD have been suggested, based on different functions of local dose effect. As
shown by Niemierko [54] and Seppenwooldeetal. [43] EUD can be calculated by
  LED:dee = E(EUD) « EUD=E"! (sewa) (2.3)
where E(Dj;) is the local dose effect function. Consistent with Lyman’s model[51],
Mohanetal. [55] chose a power-law local effect function when deriving an ’effective
dose’. Later Niemierko [56] used an equivalent expression for his generalised EUD!:
 EUD = (s20)Dy i:| (2.4)
1Niemierko, however, used the parameter a instead of n, where a = 2
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Other expressions have been suggested for the equivalent uniform dose (or similar
concepts), such as one based on the LQ model[54] where equalcell kill is assumed to
cause equal effect, and thus is most suitable for evaluating the dose distribution in the
tumour, and one based on the relative seriality model (section 2.1.3) [57]. However,
equation 2.4 is the one most commonly used, and hereafter EUD will always refer to
Niemierko’s generalised EUD.
The probit function combined with the EUD DVH reduction scheme has three
parameters. Here ¢ = EUD and 50is generally called TDso (c.f. figure 2.1). This
model is equivalent to the LKB model which instead of EUD calculates an effective
volume:
 
\'n vy.
Here Dp is a reference dose, normally the maximum orprescription dose. Very is
actually not a volumesince it is dimensionless, but rather a volume-weighted dose-effect
normalised to Dr. In this model ¢59 appears to be represented by the ’partial volume’
TDso9, normalised to Dr,
and ¢ by Dp, which implies that 59 has a different value for different DVHs. However,
if the expression for t (equation 2.2) is manipulated it can be shown that ¢ equals EUD
and ¢59 = T'Dso, and thus the LKB modelis identical to the EUD model:
I/n 4,D; V;
Bt) Vics_
I/n y, ie
R.) Viot )
1/n .D; V; ,Dr (x. (2s) a) — TDs0 _ (5 p;!” wey) -TDs BUD —TDso
mm: TDs0 mM: TDs0 — Mm: TDs0
 
 
Drp—-TD ;Dr—-TDs0pr _ _ 2 (=.t= m-TDs0Pr
m-: TDs0 (= (
 
   
 
Thus, these models are the same, and when used it will be called the LKB model,
because of its historical importance and current popularity, but generally the EUD
formalism will be used, due to its greater transparency.
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A two-parameter version of the LKB modelis the mean dose model. Here n = 1
and EUDis equal to the mean dose:
V;
Viot
 EUD = 5) D; (2.7)
i
Thedifference in the local dose effect assumed by the LKB model and the mean dose
modelis illustrated in figure 2.2. For the mean dose model this is a straight line. The
power-law local dose effect function used by the LKB modelis an approximation of an
s-shaped curve for low effects [58]. For some organsa high levelof local tissue damage
is acceptable if limited to a small volume, and in this case the linear or power-law
approximations of the LKB DVHreduction schemes might not be the best choice. The
versions of the critical volume model below offer alternative shapes of the local dose
effect function.
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Figure 2.2: The shape of local dose effect functions assumed by the different DVH
reduction schemes used by the LKB model, the mean dose model, the four-parameter
critical volume model, the three-parameter critical volume model and the Vp;_, model
respectively.
2.1.2 The critical volume model
The critical volume model was developed as a biological model based on the LQ model
and Poisson statistics (see section 2.2.1). This section will focus on a purely empirical
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model used by the Dutch NKI group [59, 43], which resulted from a simplification of
the original critical volume model. The local dose effect function (see figure 2.2) is
1E(D;) =
1+
(Dso/Di¥’ (2.8)
and the summary measure which can be used with the probit function is the relative
damaged volume:
(2.9) Vio= dBD)
The modelis namedafter the critical damaged volume parameter, $59. The other three
parameters of the critical volume model are m, Ds and k.
When this modelis fitted to clinical or experimental data it is often difficult to
find a unique best estimate for both local effect parameters, especially the parameter
representing the slope of the local dose-effect function, k [60, 43, 44]. Therefore,it is
moreefficient to assume that the slope of the curve is known, which reduces the model
to a three-parameter model. Jin et al. [61] have proposed this one-parameter s-shaped
function for the local dose effect:
ae+ 1/2 when D; < 2Ds0E(D;) = . (2.10)
1 when D; = 2Ds50
which assumes a moderate slope and is symmetric around Ds9 (see figure 2.2). This
function replaces equation 2.8 in equation 2.9.
Where a steep dose-effect function is more appropriate the Vp;;, model is to be
preferred. This model assumes that volumesreceiving doses above Ds are completely
damaged, whilst volumes with lower doses are spared. The local dose effect function
(see figure 2.2) is:
0 D; < DsoE(Dj) = (2.11)
1 D; > Dso
In this section three alternative local dose effect functions have been presented
(equations 2.8, 2.10 and 2.11). All three version of the critical volume model can be
fitted to a dataset and the one that performs the best be chosen (see section 3.3).
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2.1.3. The relative seriality model
Unlike the models described above therelative seriality model [47] is not based on the
probit function. The DVHis expressed as a probability-volume histogram (also called a
risk histogram [62]):
 P(D;) = 27-2?(ert z55)) (2.12)
where Dso is the dose causing 50% NTCPif the organ is uniformly irradiated, and 7¥ is
the slope at the steepest point of the curve. The NTCPis given by
Vi 1/sNTCP = (: —~|[[G@- P(D)’)“ , (2.13)
a
 
where s is the volume-effect parameter. For high values of s (~ 1) this function assumes
that the FSUs are organised predominantly in a serial manner, whilst for low values of
s a large number of FSUsare assumedto function independently of each other.
It will be shown in chapter 7 that the performance of the relative seriality model
and the LKB model often are remarkably similar when fitted to the same dataset. This
might be due to the features they have in common: a doseeffect calculation based on
knowledge about whole-organ uniform irradiation, and a power-law histogram reduction
(probability-volume histogram and DVH,respectively).
2.2 Mechanistic and non-DVH based NTCP models
The models described in the previous section are general enough to be suitable for most
clinical datasets, and though they can beinterpreted to reflect certain assumptions
about the underlying biology they are essentially empirical, and NTCP estimates can
fill the same purposeas empirically derived dose-volumeconstraints [42]. A number of
different models canbe fitted to a clinical dataset and the one which performs the best
(see section 3.3) can be selected for future treatment plan evaluation for example.
Since the DVH reduction schemes are empirical there is an uncertainty in the
actual risk connected with a certain value of ¢, a population standard deviation
due to the different dose distributions giving similar ¢ but potentially associated
with different NTCP. In somesituations it is of interest to explore the potential of
more specialised models, which more explicitly reflect the pathogenesis of a certain
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complication. Typically, this is the case where non-local effects of irradiation cannot
adequately be captured by an empirical DVH reduction scheme, such as non-local repair
effects for very small fields of very high doses achieved by heavyion irradiation [42], or
the so far unexplained additive damage by volumesof very low doses to that caused by
volumesreceiving significant doses [63]. Here, the DVH reduction schemesfall short
since the damage in organ subvolumescontribute independently to the total damage.
Another reason to explore mechanistic models is the potential to use them for
untried treatment techiques. A model which adequately reflected the pathogenesis of a
complication would be more reliable than an empirical model when extrapolating to
dose distributions verydifferent from the current clinical experience.
If a tissue consists of FSUs which are damaged independently by radiation andif
organ function depends on the integrity of someorall of these FSUs, binomial statistics
can be used to calculate NTCP. This approach is altogether different from the empirical
use of the models described so far, where the main concern is to detect statistical
patterns in a dataset. A model developed around the FSU concept aims to estimate
the NTCP based on the knowledge of radiobiological mechanisms, independently of
previously collected clinical data. Model parameter values can be chosen based on
experimental measurements or reasoning about the organ architecture.
2.2.1 The mechanistic critical volume model
A model developed on these principlesis the mechanistic critical volume model (62, 34, 64].
A functional reserve parameter decides how many FSUs can be damaged before a
complication occurs; the probability that this threshold is exceeded is given by the
cumulative binomial distribution (or the normal distribution if the number of FSUs
is large); and the probability of FSU inactivation is given by the LQ model. The
model was applied to the kidney and values for the numberof stem cells per FSU, the
stem cell radiosensitivity, the total number of FSUs and the functional reserve were
suggested. With such a model also the level of intra- and inter-individual variations
in the parameter values need to be taken into account, which leads to a multitude of
model paramteters. Therefore, simplified versions of the model were suggested.
The implementation of the critical volume model in section 2.1.2 relates to the
individual (rather than population) critical volume model with the approximation of
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the binomial distribution with the normaldistribution [34], but it is purely empirical
since the parameter values when fitted to a population do not represent the biological
parameters built into the mechanistic model [64].
2.2.2 Modelling spinal cord injury
A special case of the critical volume modelis the critical element model, which includes
no functional reserve. Here each FSU is crucial for continued organ function. The
binomial expression for NTCPis simpler in this case, and also in the case applicable to
the tumour where the response depends on the probability of killing every stem cell (in
this case each stem cell can be regarded as an FSU) [62, 34, 64]. The expression for the
critical element model is
NFSUNTCP =1-(1-— Prgy) (2.14)
where Prsyis the probability of inactivating an FSU and NFSU is the number of FSUs
in the organ. If equation 2.12 is used for calculating Prgy, this modelis identical to
the relative seriality model with s = 1. Alternatively equation 4.1 can be used.
Thecritical element model has mostly been applied to the spinal cord which is
typically regarded as a serial organ. However, some experimental data suggest that this
approachis not valid when small or non-contiguous volumesof spinal cord are irradiated,
and several attempts have been made to explain these results with alternative models.
Stavreva et al. [65] adapted the critical volume model to account for the contiguity of
the FSUs, and van Luijk etal. [66] developed a model which includestheeffect of tissue
repair through cell migration.
2.2.3. Cluster models
The requirement that damaged FSUs be contiguous was also adopted by Thameset
al. [67] in their cluster model. In this model a complication is assumed to occur
depending on thesize of the largest cluster of contiguously damaged FSUs. The model
was applied to paralysis caused by spinal cord injury, and later to rectal bleeding (68).
The spinal cord was considered a one-dimensional array of FSUs and the rectal wall a
two-dimensional array. Thecritical size of the cluster for rectal bleeding was explored by
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fitting the modelto clinical data with pairs of patients with similar DVHs but different
outcome, in order to demonstrate an eventual spatial effect which would be lost in the
DVHs.
Although Fenwick’s [69] parallel model for rectal bleedingis a critical volume type
model, it has many similarities to the cluster models. An s-shaped function is used to
modelthe risk of local tissue damage (telangiectasia), and the NTCPis given by another
s-shaped function based on the numberof radiation-induced telangiectasia. However,
this model does not take the spatial distribution of local damage into account.
2.2.4 The variable critical volume model
Thecritical volume tolerance method [70] and the variable critical volume model[71]
also focus on the damagedrectal wall area, but without making assumptions about
the actual tissue damage mechanism. The variable critical volume model identifies the
volume with the greatest damage for different sizes of the subvolume, and the damage
threshold for triggering a complication is higher the smaller the volume is. This is in
fact an empirical modelsinceit is fitted to datasets to determine parameter values.
2.3 Discussion
2.3.1 The role of NTCP modelling
As described in section 2.2, there are two different classes of NT'CP models, which
are useful for different purposes. When the purposeis treatment plan evaluation it is
important that the NTCP prediction is reliable, and efficiently incorporates the clinical
experience. Conformal treatment plans often generate highly inhomogeneous dose
distributions in normal tissues and such data are too complex to evaluate manually [42].
NTCP models fitted to clinical data have been ‘trained’ to identify characteristics of
DVHswhich are associated with a higher risk of toxicity, and if used together with
confidence intervals the reliability of the NTCP estimate is apparent (see section 3.2).
An ideal empirical NTCP model should classify high- and low-risk treatment plans with
high accuracy (see section 7.4.1). This will have an impact on the optimal number
of parameters, which if too high will prevent the limited size of clinical datasets from
determining the parameter values with adequate precision, and if too low will fail to
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describe the data. Therefore empirical models have been developed to be fast and easy
to use [66], and have a high degree of transparency [42].
As suggested by Withers and Taylor [72] a biologically based mechanistic model, on
the other hand, is dependent on an extensive quantitative knowledge baseof radiobiology.
These models highlight what areas need further research before a full understanding of
radiation-induced pathogenesis can lead to predictive modelling of NTCP, without the
need of statistical fitting of empirical parameter values. They also demonstrate what
can be achieved when such knowledgeis available. Thus, mechanistic NTCP modelling
is dependent on research in experimental radiobiology, but can also support and inspire
such research by generating hypotheses and suggesting explanations. However, the
applicability of these models to treatment planningis still limited, due to the many
unresolved issues of normal-tissue response mechanisms[73]. Also, biologically based
models are necessarily simplifications of reality, and it can be argued whetherthestrict
assumptions involved lead them too far away from reality, and whetherit is even possible
to develop a comprehensive biologically based NTCP model [46].
2.3.2 The LQ model
When NTCPis calculated for inhomogeneousdosedistributions the DVHs should always
be normalised, e.g. to 2-Gy equivalent doses according to equation 1.3 [74]. Otherwise,
if ‘physical’ total doses are used the contribution from damage to low dose volumes is
overestimated, due to the non-linear nature of the relationship between dose andcell kill.
Unlike the mechanistic NTCP models described in section 2.2, the LQ model used to
normalise DVHs has been validated extensively on experimental data [16], which justifies
considering the normalised doses as given, rather than part of the fitted NTCP model.
Someinvestigators, though, havefitted the parameter a/to their dataset together with
the NTCP model parameters, when used with an empirical model. In this case the LQ
modelis also considered empirical. When used in a mechanistic sense, on the other hand,
the value of a/{ is chosen based on experimental results. This is not to say that a/f is
generally very precisely known, but the choice of a/( seems to have weak influence on
the fitted NTCP parametervalues [75, 76]. To be on the safe side the calculations can be
repeated for a few different values around the standard a/8 = 3 Gyfor late-responding
normal tissues and a/8 = 10 Gyfor early-responding normaltissues and tumours [15].
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However, care must be taken to use a version of the LQ model appropriate to the
treatment technique. In its simplest form (equation 1.2), complete repair of sublethal
damage between fractions and absenceof proliferation are assumed. Thus, when applied
to hyperfractionated treatments(if the interfraction interval is less than about six hours)
and/or to early responding normal tissues, time effects must be included [77, 78]. Also,
when a treatment takes longer than 15 — 30 minutes, intra-fraction repair decreases the
effect of the fraction dose and must be taken into account [77]. This is important when
normalising DVHs for brachytherapy as well as time consuming conformal treatments
like stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT)
and tomotherapy. However, as pointed out by Stewart and Dorr [19], the influence of
treatment timeis still not well understood andit is likely that cell migration as well as
repair of sublethalcell injury influence the tissue response over time [14]. Therefore,
calculations depending on timeeffects should be treated with caution.
2.3.3. The volumeeffect
The rationale for efforts to conformalise radiotherapy is the hypothesis that reduced
volumesof normaltissues irradiated to high doses are associated with lower complication
probability. When the number of beams used to deliver the tumour doseis increased
the normal-tissue volume receiving high doses can be decreased, but the larger number
of beams leads to larger normal-tissue volumes being irradiated, though this dose is
relatively low. The integral dose to the normaltissues aroundthe target is approximately
constant for different photon beam arrangements [79, 80], but the effect of increasingly
inhomogeneous dose distributions is difficult to predict. When a traditional endpoint
is considered, small volumes of organs with a large functional reserve might tolerate
extremely high doses, but then a new typeof toxicity might be encountered which has
a different dose-volume dependence. Also, it might be considered safe to irradiate large
volumes to low doses, but in addition to smaller volumes of high dose the damagein
these volumes might not be negligible [79, 63]. The risk associated with different dose
distribution characteristics remains an important field of research [81].
One way of addressing this issue is to ask whethera lot (of dose) to little or a little
to a lot is to be preferred. A study on lung treatment data concluded that dispersing
the energy over large volumesresults in a lower NTCP [82], whilst another analysis
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showed that organs with a large functional reserve are likely to have a higher NTCP if
treated with low doses to large volumes[80]. Serial organs, on the other hand, benefit
from suppressing the highest doses rather than the volumesreceiving low doses. In
conclusion the question of a lot to a little or a little to a lot is over simplified. The
answer depends both on the organ architecture and on how high the dose in the ‘low’
dose volume is [79, 82]. The response of tissues with radiosensitive FSUs would be
expected to depend on lower doses, and for conformal treatments to be effective the
‘low’ dose given to large volumes would have to be low enough not to causesignificant
FSU damage[34].
A related issue is the existence of a volume threshold such that there is no limit to the
dose which can be delivered to an organ fraction below this threshold. This is mostly a
philosophical question introduced by differing extrapolations from different models [35],
since there are practical limits to the dose that can be delivered to a subvolume without
causing excessive damage elsewhere. However, with SBRT exceptionally high doses
can be delivered with very low incidence of complications, which seems to support this
hypothesis. Schultheiss [33] suggests that all organs have (endpoint specific) volume
thresholds, but that in some cases these are too small to beclinically relevant.
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Chapter 3
Statistical Methods for Model
Fitting and Evaluation
3.1 The likelihood function
This section will focus on the methodologyforfitting empirical NT'CP models to datasets,
and methods for evaluating the modelfit are described in section 3.3. It is assumed
that the data set consists of DVHs for the individual patients and binary typeclinical
outcome data, e.g. yes/no for grade 2 rectal bleeding.
3.1.1 Parameter estimation
When modelling binary data the maximum likelihood method is the parameteresti-
mation method of choice (45, ch. 3]. The best estimates of the parameter values are
calculated by maximising the likelihood of observing the actual outcome data for the
corresponding dosedistributions D; [83, ch. 8]. Let Q; = 1 for patients who suffer a
complication, Q; = 0 for patients without the complication, and NTCP;(D;,a) be each
patient’s NTCP estimated for a given dose distribution and parameter set a. Then the
likelihood P of observing Q for NTCPis given by
P=|[Nrcp*(1-NTCR)', (3.1)
i
where 7 = (1,2,...,N) are the patients in the dataset. The task of finding the optimal
parameters then consists of maximising equation 3.1 in terms of the parameterset a,
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Figure 3.1: An example of a probability distribution for the mean dose model.
or equivalently the log of equation 3.1:
L=)5 > Qin(NTCP,) + (1- Qin (1 — NTCR,) (3.2)
i
The maximum likelihood parameter estimate is a point in the full probability
distribution. Figure 3.1 shows this probability distribution for the two-parameter
mean dose model(section 2.1.1). This probability surface is created by the likelihood
function 3.1 for all the combinations of parameter values in the chosen parameter space,
normalised by dividing the distribution by its integral [84, 85]. The maximum likelihood
estimate of the parameter values is at the peak.
An alternative choice of parameter estimate is the central interval estimate whichis
calculated by projecting the probability distribution onto each parameter axis in turn
(figure 3.2), and selecting the central parameter value!. Since the probability function
generally is not symmetric the maximum likelihood and the central interval estimates
are different. A central interval estimate of the confidence interval (CI) of the parameter
estimate can also be derived from the projection of the probability distribution; see
figure 3.2. The 68% CI is given by the parameter values where the integral of the
function below and above the values respectively is 16% [85].
 
1The central value is the parameter value for which the area under the curve is equal oneither side.
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If the maximum likelihood methodis used without calculating the full probability
distribution it is important to use an optimisation algorithm which converges to the
global minimum,e.g. simulated annealing, since many datasets produce probability
distributions with more than one local minimum.
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Figure 3.2: Projection of the probability distribution in figure 3.1 onto each of the
parameter axes, from which the 68% confidence intervals can be calculated.
3.1.2 NTCP estimate confidence intervals
The probability distribution in figure 3.1 can also be used when estimating the NTCP
with Cls for a given DVH. The NTCPfor this DVHis then calculated for the same param-
eter combinations as for the probability distribution; see example in figure 3.3. Further,
a histogram is calculated from the NTCP distribution, weighted by the corresponding
likelihood values in the probability distribution. The resulting NTCP histogram in
figure 3.4 gives the NTCP estimate with ClIs for the DVH whichfigure 3.3 corresponds
to.
Thus, the probability distribution is created based on an appropriate dataset with
clinical and dosimetric data, and when used to estimate the NTCP for a given DVH a
unique NTCPdistribution is constructed, and the probability- and NTCP-distributions
together yield a DVH-specific NTCP histogram.
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Figure 3.3: NTCP distribution for a DVH, for many alternative combinations of model
parameter values.
The NTCPestimate in figure 3.4 is based on the full probability distribution for the
model parameter values, not only the maximum likelihood estimates. The confidence
interval expresses how certain this estimate is, based on the clinical experience collected in
the dataset used to build the probability distribution. This means thatif, hypothetically,
many patients received dose distributions to the organ at risk giving exactly the same
DVHs, and divided into cohorts, the complication rate in 19 out of 20 of these cohorts
would fall within the 95% CI.
The width of the CI is influenced by lack of information on several levels. Firstly,
if the model is inherently unsuitable for summarising the collected dataset (e.g. too
few parameters, unrealistic local dose effect function) the parameter estimates will have
large uncertainties, which translate into the NTCP estimate CIs. Secondly, since the
modelis fitted only to dose-volume data, confounding factors, such as inter-patient
variation in radiosensitivity and health status, always decrease the power of a model
to describe the observed clinical outcome (assuming no patient-specific information
except the DVHis included in the model), resulting in larger Cls. Thirdly, also the
loss of information in the reduction of the dose distribution to a DVHis a potential
confounding factor. Fourthly, the parameter Cls are large if there are limitations in the
clinical experience due to the dataset being too small or containing very similar DVHs.
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Figure 3.4: NTCP histogram giving an NTCP estimate with confidence intervals for a
given dose distribution, based on previously collected clinical data.
If the model has an appropriate summary measure it should yield large Cls for a
DVHwhichis very different from the DVHsin the dataset used to create the probability
distribution [85, 43]. For example, if the LKB modelis fitted to a dataset with close to
uniform irradiation of the organ at risk, there will be little experience of the volume
effect of the organ in this dataset, and the volume parameter n will have a large CI. This
will result in larger CIs for a new patient with an inhomogeneous dose distribution than
a patient with a uniform one. In this way new treatment techniques could be explored
by simply making sure the upper limit of the NTCP CI for patients doesn’t exceed a
clinical tolerance level. However, since it is unlikely that the DVH-based models extract
all the important dose-volume-response information from a dataset, such faith in the
Cls is not justified. This is confirmed by a comparison of NTCP estimates with Cls
for different models, based on the same dataset and applied to the same DVH but
where the Cls do not overlap, as shown in section 7.4.1. Therefore it is important that
users understand the mechanisms of the NTCP model and what features of the dose
distributions cannot be captured by the model [42].
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3.2 Application: individualised dose prescription
The following analysis [86] highlights the importance of the use of NT'CP confidence
intervals.
The clinical use of complication probabilities derived from NTCP modelsis limited
by the uncertainties in the model parameters, which are derived from responses observed
in a population of patients. Associated CIs would give the clinician valuable information
about the uncertainty in the NTCP prediction, for a given dose plan andprescription
dose. The aim of the work described in this section is to show how such confidence
intervals can be derived from the literature or from localclinical data, and used together
with estimates of TCP to facilitate individualised dose-prescription.
DVHsfrom 31 patients receiving lung tumour radiotherapy at Clatterbridge Centre
for Oncology (CCO) were used to illustrate the potential of including NTCP CIs
in individualised treatment planning. All DVHs were normalised to 2-Gy fractions
according to equation 1.3, using a value of a/G = 3 Gy. The data used to build
NTCP parameter probability distributions were mean lung dose (MLD) andradiation
pneumonitis data from the literature; see below. Since the dose-volume data available
was MLDrather than DVHs, two-parameter versions of the LKB (mean dose model;
see section 2.1.1) and relative seriality models were used. When D; = MLDforall i the
relative seriality NTCP is given by equation 2.12 and is independent of s. Similarly,
when applying the fitted models to the CCO DVHsfor lung minus gross tumour volume
(GTV), the DVHs were reduced to the MLD and the two-parameter models were used
to calculate NTCP.
TCP was calculated for the planning target volume (PTV) DVHs with the Marsden
model [87]:
TCP, TCP(a)e"*%da, (3.3)a=e
where, for a given a
d, ttreat—tla
TCP(a =econdaf)+82
Equation 3.3 gives the average TCP for a population with different values of a. The
following parameter values were used: mean radiosensitivity, @ = 0.31 Gy?! with
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standard deviation a, = 0.062 Gy", a/8 = 10 Gy, clonogen density p = 10° cm™®,
clonogen doubling time 7.7 = 3 days, and time toproliferation start tigg = 21 days [88].
The total treatment time ttreat Was assumed to be 28 days.
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Figure 3.5: Grade > 2 radiation pneumonitis rates for different MLD [89, 90, 91, 92, 82],
with corresponding Poisson uncertainty estimates. Dose-response curve from maximum
likelihood estimates of LKB parameters TDs9 and m (n = 1 for MLD), and Monte
Carlo 68% confidence intervals. The Monte Carlo confidence intervals are based on 5000
sets of parameters.
NTCPparameters werefitted to clinical data for grade-2 radiation pneumonitis (RP)
versus MLDcollected from theliterature [89, 90, 91, 92, 82], first using the maximum
likelihood method, as in figure 3.5 for the LKB model. In these publications patients
had been binned according to MLD,so all patients in one bin were assumed to have the
same MLD,and the numberof respondersin the bin wasgiven by the corresponding
complication rate. In figure 3.5 the 68% confidence interval for the fitted curve was
derived using a Monte Carlo method, by randomly sampling 5000 artificial datasets from
the real dataset, assuming a normal distribution of the uncertainty in the data points.
The probability distribution (PD) method (section 3.1) was used to calculate NTCP
with CI for the individual CCO DVHs(for lung-GTV). Also TCP and complication-free
control (CFC) were calculated (for the GTV DVHs), for a range of possible prescription
doses; see the result for one patient in figure 3.6. CFC equals TCP(1—NTCP) and
estimates the probability of a ‘successful’ treatment outcome.
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Figure 3.6: LKB (() and relative seriality (x) NTCP with 95% confidence intervals,
compared to an accepted level of 10% grade > 2 radiation pneumonitis, TCP (0) and
complication-free control (7) for a typical patient, for a range of prescription doses.
The PD methodgavethe following LKB model parameters: T'Ds59 = 30.5 Gy (68% CI:
28.6-33.1 Gy) and m = 0.449 (0.412-0.494), andfor the relative seriality model Ds = 32.7
Gy (30.4-35.8 Gy) and 7 = 0.722 (0.668-0.779). These estimates are similar to published
parameter estimates from clinical studies, e.g. [93, 43]. This indicates that the PD
method based on MLDdatafrom theliterature is consistent with other fitting methods.
Ideally, if enough local clinical data are available, the NTCP with CI can be calculated
with a three-parameter PD, based on DVHsinstead of MLD asinput data. As more
local outcome data is accumulated, the CIs on NTCP estimates will decrease and, in
principle, be tailored to the treatment techniques of the centre concerned.
In a study about the importance of NTCP Cls for treatment planning Langer
concludes that “the effect on tumour dose of relaxing a constraint within its range of
uncertainty should be made available to physicians involved in theselection of treatment
plans” [46]. Together with an estimate of TCP, the NTCPfor a rangeof prescription
doses can be a guide for the clinician in finding the optimal dose, as a trade-off between
local control and complication probabilities. The CI of the NTCP estimates give an
indication of the uncertainty in the (population averaged) predicted response of the
patient, for a given dose plan andprescription dose.
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Currently at CCO, for the standard 55 Gy to the tumour, the patient in figure 3.6
would achieve (on the average) NTCP = 5.5% and TCP = 31%. However, with individ-
ualised dose-prescription she/he might receive 73 Gy by accepting mean NTCP = 10%,
resulting in a significantly increased TCP (86%). Alternatively, 61 Gy may be prescribed
if the dose was conservatively based on the upperlimit of the CI not exceeding NT'CP =
10% (TCP = 55% in this case). The individualised prescribed dose mayalso be influenced
by the health status of the individual patient, taking co-morbidities into account.
3.3. Model accuracy
After fitting a model to a dataset it is important to assess the accuracy, or goodness-of-fit
(GOF), of the model. For a continuous response variable the model accuracy depends on
the residual variance, but this approach cannot be applied to binary response variables
since in this case the aim of the model fitting is not to draw a curveas close as possible
to data points.
Depending on the purpose of the NTCP modeldifferent methods for assessing the
accuracy of the model fit have been used. Here only the accuracy of models with
predictive purposes will be discussed. In this case the purpose of the assessment is to
estimate the strength of correlation between the predicted NTCP and outcome,or the
powerof the model to correctly separate responders from non-responders.
If the purpose of the assessment of accuracy is mainly to compare the performanceof
different models, only a relative GOFis necessary. However, if the models have different
numbers of parametersit is important to consider the principle of parsimony; models
with many parameters are generally able to fit datasets better, but this is of no use if
the model is overfitted. In this case the model interprets spurious effects as universal
and whenapplied to a different dataset it will perform poorly.
3.3.1 ROC analysis
A method which has been shownto be useful for assessing the predictive ability of a
dose-volume metric [94] is receiver operating characteristic (ROC) curve analysis [95,
ch. 2]. This method has also been recommended for NTCP analyses by the QUANTEC
study [96].
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To create the ROC curve the true positive ratio (TPR) and the false positive ratio
(FPR)are calculated for a series of NTCP cut-offs. The individuals in the dataset are
labeled positives and negatives if their calculated NTCP is above or below the cut-off,
respectively. The positives who actually suffered a complication are true positives and
those who did not are false positives. Similarly, the negatives are either true or false
negatives. The TPR,or sensitivity, is the number of true positives divided by the
number of actual responders, and the FPRis the numberoffalse positives divided by
the numberof actual non-responders. 1 — FPRis called the specificity.
The values of the TPR and FPR depend on the cut-off, and the ROC curveis the
relationship between FPR and TPRasthe cut-off is decreased in small steps from
NTCP=100% to 0%; see figure 3.7. At a cut-off of 100% no individuals are labeled
positives, so TPR=FPR=0. Asthe cut-off is decreased increasing numbersofindividuals
will be accurately labeled positives, resulting in a growing TPR. At some point thefirst
false positive will be identified and then FPR will also start growing. The better the
responders and non-responders are separated by the model, the closer the curve will
tend to the top left corner. If the ROC curve follows the diagonal the modelis no better
than a random labeling of positives and negatives. It is therefore logical to use the area
under the curve (AUC) as a measure of model accuracy.
The AUCis not only an intuitive measure of model accuracy but also, in fact, the
probability that a randomly chosen responder has a higher NTCP than a randomly
chosen non-responder [95, ch. 2}. Moreover, when the AUCis calculated with the
trapezoidalrule it is also identical to the two-sample Mann-Whitney U-statistic [97].
As a general rule, a model with AUC>0.9 has a high accuracy, a model with an AUC of
0.7-0.9 has moderate accuracy and a model with an AUCof0.5-0.7 has low accuracy [98].
Since the AUC is equal to the Mann-Whitneystatistic it can be calculated as follows,
rather than from a plotted curve [97, 95, ch. 4]:
no m1A=W%,¥)) (3.5)
j=1 i=1
Here A denotes the AUC for a given fitted model, n, and ng are the numberof responders
and non-responders, X; the NTCP estimate for responder 7, Y; the NTCP estimate for
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Figure 3.7: ROC curve for a dataset with 200 individuals. The area under the curve
was calculated with the trapezoidal rule.
non-responder j, and
1Y<XW(X,Y) = .
0 Y>xX
In order to calculate confidence intervals for the AUC and test for significance of a
difference between the AUC for different models the covariance matrix C needs to be
calculated. If k models are compared C is a k x k matrix. According to the method of
DeLongetal. [97, 95, ch. 4-5] the following variance components are defined for modelr:
oe(XP,Yf)  (¢=1,2,....m1)
~ 19 4
Me(XP,Yf) (7 =1,2,....n0)
Also, the elements of k x k matrices Cx and Cy are
~— S-(v7(X;) — Ar)(v#(X;) - A*)—1de =I
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Then the covariance matrix is given by
162 2a4a (3.6)
The 68% confidence interval for A” is calculated from the square root of the variance
which is given by C,.,.
A, given by equation 3.5, is an estimate of the ‘true’ AUC,A, given by an infinitely
large dataset. To detect a statistically significant pairwise difference between the AUCs
in A the following chi-square distributed test statistic is calculated:
Z=(A—A)E/(LCL)"L(A Ay (3.7)
The vector L is called the contrast and indicates which models are being compared. If
e.g. k = 4 and model 1 and 3 are compared, L=(1 0 -—1 0). When two models
are comparedthe test has one degree of freedom and a p-value can be calculated from
the chi-square distribution for Z. Conveniently the unknown values in vector A always
cancel out, since the sum of the contrast vectoris 0.
The use of AUC as a GOF measure is convenient since it addresses the specific
question of how well a model can be expected to predict the risk of toxicity, and
furthermore the actual value has a relevant interpretation as the model’s ability to
correctly classify individuals as high- or low-risk cases. It should be noted however
that the AUC is dataset dependent. Consider a set of DVHs which largely fall into
two risk groups (e.g. if typically a very small or very large volume of normal tissue
wasirradiated). In this case several models might easily correctly classify responders
and non-responders, whilst for a dataset containing many DVHs with NTCP ~ 50%
all models have a greater challenge. This will lead to lower values of AUC.It is also
important to note that the AUC is independent of the number of model parameters
and does not safeguard against overfitting.
37
3.3.2 The Akaike information criterion
If the only concern is the relative performanceof a set of NTCP models, a convenient
GOFmeasureis the value of the maximum log-likelihood. The model which makes
the observed outcome the most probable is the best model. However, like the AUC
the maximum log-likelihood is vulnerable to overfitting. Instead it is better to use
the Akaike information criterion (AIC) [99, ch. 2], which is based on the maximum
log-likelihood (ZL) but gives advantage to models with a low numberof parameters
(Npar):
AIC = —2L + 2Npar (3.8)
Calculating AIC is asymptotically equivalent to cross-validating the model [99] on
data subsets. However, the use of AIC is only valid for large datasets (99, ch. 2]. This
method, and similar information criterion methods, have recently become popular for
comparing the performance of NTCP models, e.g. [100, 101, 102].
3.3.3. The bootstrap method
Anempirical bootstrap technique can be used to compare the GOFofdifferent mod-
els [103]. With this technique many replicate datasets of the samesize as the actual
dataset are generated, by randomly sampling data points with replacement from the
original data [100]. The modelis fitted to each of the replicated datasets and confidence
intervals for the original model parameters and the log-likelihood can becalculated.
If this is done for two different models an empirical probability distribution of the
difference between the log-likelihoods is easily derived. A significance test based on this
probability distribution then showsif the difference between the log-likelihoods for the
original dataset is statistically significant [75]. A disadvantage of this methodis that it
is computationally expensive.
3.3.4 Other goodness-of-fit methods
A GOF method used by Jackson et al. [104] has been very popular. They assumed
normality of the log-likelihood function in order to estimate the expected maximum
value of L and its standard deviation (see appendix in [104]). The probability offinding
a lower value of LZ (and thus a worsefit), for an equivalent dataset, is given by comparing
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the observed value of L to the normal distribution with the calculated expected value
of L and its standard deviation as mean and standard deviation respectively. Thus,
this method checks whether the non-random features influencing the outcome of the
patients are adequately accounted for by the model prediction. However, the usefulness
of this methodis limited by its assumption that the value of L has a normal probability
distribution.
The GOF methodused by van Luijk et al. [60], the likelihood ratio test, is also based
on the likelihood function but does not assume normality of the probability distribution.
However, since this method operates on groupsofidentically treated individuals [45],
it is more appropriate for experimental than clinical data. Similarly, Spearman’s rank
correlation, which has been advocated for NTCP modelling {105, 46], is not applicable
to binary outcome data but can be used when the outcomeis graded.
Two methodology and/or dataset dependent measures of GOF, which are suitable to
use with binary data and do not make assumptions about the shape of the probability
distribution, are the Hosmer-Lemeshowstatistic and pseudo R? metrics [45]. The
Hosmer-Lemeshowstatistic is a chi-square statistic based on the observed and the model
predicted complication rates in groups of individuals belonging to bins of predicted
NTCP.Since the value of this statistic depends on how the data are binned theresult
is indicative rather than absolute.
A pseudo R? is a measure ofthe variation in the response explained by the model,
and it ranges from 0 for a very poor model to 1 for an ideal model. The most popular
pseudo R? was proposed by Nagelkerke [106]:
2/NMo
petMattes) 3.9~ 2/N ( . )
where M(a) is the value of the likelihood function for the fitted parameter values
(the maximum likelihood), Mo is the maximum likelihood for a model with a constant
parameter only (called the intercept model for logistic regression), and N is the number
of individuals in the dataset. In this way the modelfit is compared to a poor modelfit,
and the larger the difference, the better the fitted model. The pseudo R? cannot be
interpreted independently or compared for different datasets, but is useful for comparing
the performanceof different models for the same dataset. It was used by Rutkowska et
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al. [107] for a logistic regression analysis in order to assess the strength of correlation
between dose-volume parameters and outcome.
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Chapter 4
A 3D Mechanistic Computer
Model of Normal-Tissue Effects
after Radiotherapy
The aim of this work was to develop a mechanistic model of normal tissue that can
be used for simulating radiotherapy treatments. This chapter describes this model in
detail. The ‘patient’, or organ, is represented by a 3D array of volume elements (voxels)
containing FSUs, as well as doses representing the dose plan. Thus the dose in a voxelis
assumed to be uniform, and the number of FSUsrecorded in the voxel after ‘treatment’
depends on this dose and on the number of FSUsin the voxel before treatment. The
model is based on two assumptions relating to overall organ injury and local tissue
damage, respectively.
4.1 Organ injury
Thefirst assumption concerns the organ response to local tissue damageafter irradiation.
It is assumed that every organ hasa critical functioning fractional volume (CFV), which
is the smallest fraction of the organ that, if its function is lost, causes a complication.
This loss of function is assumed to occur when the number of surviving FSUs in the
CFVis lower than a certain threshold value (FSUmin). In other words, in order for the
organ to retain its function the numberof surviving FSUs in any organ subvolume may
not fall below FSUmin; see illustration in figure 4.1.
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Figure 4.1: The 3D model represents an organ by an array of FSUs. Here the density
of surviving FSUs per voxelis illustrated by the colourwash. The CFV(indicated by
the wire-frame regions) here has a size corresponding to a semi-parallel organ; it can
take any position in the normal tissue, but does not extend into the GTV.If a CFV in
any position includes too few surviving FSUs (i.e. below FSUmin), a complication is
triggered.
As a consequence, an organ with a small CFV (equivalent to serial tissue architecture)
can suffer a complication even for a relatively small volumeof severe tissue damage,
whilst a large CFV (parallel architecture) allows organ function to be maintained despite
damage to moderate volumes. The CFV can take any value above zero and less than
or equal to 1, thus modelling the volumeeffect in a continuous fashion over a range
of organ architectures; as the CFV goes from being very small for a serial organ to
large for a parallel organ, it takes account of damage over an increasing number of
contiguous voxels. Moreover, this volumeeffect representation also takes into account
the spatial distribution of tissue damage when deciding whether a complication occurs.
For example, in an organ with an intermediate-sized CFV, two small dose hotspots
might cause a complication, depending on the distance between them. The model can
also simulate the effect of an initially inhomogeneous density of FSUs, which could be
caused by the natural tissue architecture, previous organ damageor the presence of a
tumour, though this possibility is not explored in this thesis.
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4.2 Local tissue damage
The second assumption defines the local effect of radiation on the tissue as a stochastic
inactivation of FSUs. Here an FSU is defined as the largest tissue volume of damaged
cells that can be regenerated by a single stem cell (see section 1.1.3). In some organs
this might be the smallest unit performing a function in the tissue in question, e.g. if
cells are prevented from migrating between such anatomical structures [29].
If complete repair of sub-lethal damage between fractions and absenceof proliferation
of normal tissues during the course of treatment are assumed, the stem cell surviving
fraction is given by equation 1.2. As discussed in section 2.3, the normal-tissue endpoints
considered in this case are late effects, which are caused by depletion of slowly prolif-
erating stem cells, and the dose is assumed to be delivered at the rate of one fraction
per day. For rapidly proliferating normal-tissue stem cells and/or hyperfractionated
(i.e. twice a day) treatments, time effects can easily be incorporated into the model,
however, by using the time-dependent version of the LQ model {78}.
The probability of inactivating one FSU (Prsu) is equal to the probability of lethally
damaging every stem cell in the FSU, given by Poisson statistics if the number of stem
cells per FSU, Nc, is large (analogous to TCP modelling {108]):
Prgy = eNeoSF (4.1)
NeSU) in a voxelis stochastic, and therefore sampledThe numberof surviving FSUs(
from a binomial probability distribution, given Ppsy and the numberof pre-treatment
FSUs per voxel (NfSU). However, for large NFS” such that the binomial standard
deviation < 1%, the numberof surviving FSUsis well approximated by the binomial
mean and will be assumed to be deterministic:
N§SU = NgSY(1 — Prsu) (4.2)
A similar approach has previously been taken by several other authors modelling NTCP
mechanistically [62, 109, 34, 64].
Thus, equation 4.2 (or the randomly sampled Neov) applied to every voxel in the
dose distribution gives a distribution of local tissue damage. Organ injury, however,
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also depends on the volumeeffect which is modelled by the CFV. A complicationis
triggered if the numberof surviving FSUsfalls below FSUmin in any CFV.
4.3 Simulations
4.3.1 Model structure
A Matlab (www.mathworks.com) script was developed which simulates radiotherapy
treatments as described above. Each step in the calculations is illustrated in the
flowchart at the end of this chapter. First, values for input parameters are chosen; the
organspecific parameters are the size of the CFV (critical functioning volume), FSUmin
(threshold for the number of surviving FSUs in a CFV), the LQ model parameters a
and a/{, Nsc (the numberof stem cells per FSU) and number of FSUs/voxel. When
data including inter-patient variation in radiosensitivity and health status are simulated,
a mean and standard deviation for a and the number of FSUs/voxel are chosen and for
each treatment these parameters are randomly sampled and recorded. The treatment
specific parameters are dose per fraction and numberoffractions.
Next the 3D array of a dose distribution is loaded. A set of such arrays was usually
prepared in advance, as described in section 4.3.4, but could also imported from a
treatment planning system. The doses are converted to EQD2 according to the selected
treatment specific parameters. A PTV is defined based on the dose distribution as
described in section 4.3.4, and a GT'Vis defined based on the PTV. A DVH and
other dose-volume parameters for the normal-tissue dose distribution are calculated and
recorded.
An array for the FSU distribution is created, which is of the same size as the
dose distribution array. Since in the model local tissue damage is represented by
FSU inactivation, this array initially represents the healthy normal tissue, and after
irradiation the damaged normaltissue. In the FSU distribution, elements not belonging
to the normaltissue of interest are set to zero (outside the organ and in the GTV), and
within the organ it is uniform in its healthy state in the work presented in this thesis,
although the modeleasily handles inhomogeneous FSU distributions. The distribution
of surviving FSUsafter applying the dose distribution is calculated on a voxel basis
with the equations in section 4.2.
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Next the number of FSU survivingin all possible CFVs throughout the organ should
be calculated. When the model was developed, a few different approaches were tried
and discarded before a satisfactory one was found. The main difficulty was to get the
CFV to adapt its shape around the organ surfaces appropriately.
4.3.2 Modelling the CFV
In the first approach the CFV was given the shape of a cube, which was built by
extending it equally in all three dimensions from one of its corners. Thus the numberof
CFVsfitting along each axis of the organ array was the organ array side length, minus
the CFVside length, plus one. For any CFV including GTV voxels, layers were added
to the CFV in each dimension such that the number of added voxels was roughly equal
to the voxels initially shared by the CFV and GTV, multiplied by one plus the fraction
of the CFV these invalid voxels amounted to (assuming that the added layers would
include an equalfraction of invalid voxels). The CFV wasthen defined as the part of
this volume which remained after excluding the GTV voxels. Figure 4.2(a) shows an
illustration in 2D of this approach. After having used this approach for different dose
distributions it was deemed inappropriate, since for somepositions and sizes of the CFV
versus GTV, the CFV took a very irregular shape with subvolumes extending far from
the centre of mass.  
Figure 4.2: Illustration in 2D of the different methods considered for identifying the
CFV (green area). The main difficulty was to make the shape of the CFV adapt to
e.g. the GTV surface (red area). In (a) the CFV was a square (cube in 3D), where the
size was increased to compensate for excluding GTV voxels. In (b) the FSU survival in
round (sphere shaped in 3D) CF'Vs was calculated with a convolution method, but this
could not account for adapted shapes of the CFV. Theorange area represents elements
shared by the CFV and the GTV. The method actually adopted, (c), identified the
CFVasthe valid voxels (non-GTV) closest to the CFV centre.
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Instead, the shape of the CFV was chosen to be a sphere, in order to let all voxels
be as close as possible to the centre of the CFV. The fastest way to calculate the FSU
survival in these spheres was found to be by convolution of a binary 3D array, defining
the shape of the CFV in one position, with the FSU survival array. This approach
was much faster than the previous one, in which each CFV wasidentified separately.
However, as the illustration in figure 4.2(b) shows, this method could not give the
FSU survival for CFVs around organ surfaces where the shape of the CFV should be
adapted. Different approximations were tried, but it was discovered that the ‘critical’
CFV generally was contiguous to the GTV, and was thus of a different shape than
the basic sphere. Therefore it was crucial to find a consistent method for adapting the
shape of the CFV to the GTV surface, and no approximation was reliable since several
CFVsoften hadsimilar levels of FSU survival to the ‘critical’ CFV.
The approach finally adopted was to label each CFV by its centre element, and
extend it to include the closest ‘valid’ voxels until the chosen size was reached (method
described below). This approach is illustrated in figure 4.2(c). When building each
CFV,every voxel of the organ array could be considered in a very large for loop, and
the closest ones selected, but this would be extremely time consuming, so instead a
vectorised method was adopted. The main problem encountered with this approach was
the size of the arrays needed for large CFVs; some arrays were symmetrical 2D arrays
with side length equal to the numberof voxels in the organ array (125,000), minus the
numberof voxels in the GTV. With 8 bytes per element this variable could be of up
to 125 GB, whichis far too large for both Matlab and the operating system to handle
(see http://www.mathworks.com/support/tech-notes/1100/1107.html). This was solved
by an iteration where as many columnsofthe array as possible (representing different
CFVs) were considered at a time. Since the FSU survival in each CFV is independent
of other CFVsthese calculations could be done either in series or in parallel.
Though this approach was conceptually acceptable it was very computationally ex-
pensive (up to 5 hours for each dose distribution on a single 2.33 GHz processor), and thus
would not have been feasible in practice without the access to the high throughput com-
puting Condor Pool at the University of Liverpool (www.liv.ac.uk/csd/escience/condor).
A stand-alone executable was developed from the Matlab source code and submitted in
parallel for different dose distributions to the pool of around 300 computers available
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to Condor (Dell PCs with Intel Core 2 processors running at 2.33 GHz). Thus, since
many patients could be simulated at once, the computation time was reduced from 4-5
months to around 36 hours for a set of 800 simulations.
Initially methods to reduce the computation time were searched for, especially for
the case of a large CFV,since this resulted in a large 2D array of CFV columns, and
was the most time consuming case. However, it was important that the CFV had the
most appropriate shape around the GTV,and since in most positions a large CFV
included GTV voxels, its shape could not be approximated without loss of consistency.
The flowchart illustrates the steps necessary to identify each CFV with the vectorised
method.
4.3.3 Implementation
Thefirst step is to identify all CFV centres, which are all elements within the normal
tissue of interest. These are given by the FSU distribution array. Once the indices of
all CFV centre elements are collected the voxels in a region around each centre are
identified as CFV candidate elements. For large CFVs these includeall normal-tissue
elements (i.e. all elements except within the GTV or outside the organ of interest).
For small CFVs, on the other hand, the simulation time can be shortened by only
considering elements within a subarray surrounding the CFV centre as CFV candidates.
This subarray has to be large enough not to constrain the shape of the CFV even when
the worst case (in terms of largest extent from the center) is considered. If no surfaces
obstruct the CF'V it takes the shape of a sphere, but close to surfaces such as organ and
GTV boundaries, the shape of the CFV adapts. Thus the worst case is a CFV between
e.g. the organ boundary and the GTV with a single layer of normal-tissue voxels. This
means that the subarray of CFV candidates has to be large enough to fit all CFV
elements in one 2D layer. All CFVs small enoughforall its elements to fit on a 2D slice
of the full 3D array are considered a ‘small’ CFV in this context. The rare situation of
a GTV approaching a corner and forcing a small CFV to stretch predominantly in a
single dimension was not taken into account as speed of calculation wasprioritised.
As a result a 2D array, A, containing indices for elements in a 3D arrayis created. If
‘N’ is the number of CFV centres, and thus normal-tissue elements, and ‘n’ the number
of candidate elements for each CFV, A is an Nxn array (NxN for large CFVs). Each
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column in A contains the indices of the CFV candidates corresponding to a given CFV
centre. Further an array, B, of the samesize as A is created, containing the indices of
these CFV centres in rows, such that each row is identical. Thus for all CFV candidate
elements in a column in A the corresponding CFV centre index is given by the same
position in B.
Next, the subscripts corresponding to the linear index values in array A are entered
into three arrays, Ax, Ay and A,. Similarly the subscripts of the CFV centres in B
are entered into three arrays, By, By and B,. This makes it possible to calculate the
distance from each CFV candidate element to the CFV centre; if C is an array of the
same size as A and thedistances are given by
 
ci = y/(bb —at)? + (bi —ai)'+ (bi — a’)’,
wherei is the same element in arrays A, B and C, and b? represents element i in array
B,. To make sure no GTV elements are included in the CF'V the values of the distance
for all GTV elements are made the same as the maximum valuein array C.
Thevalues in each column of C are further sorted in ascending order, and the linear
indices from A, correspondingto thefirst elements in this sorted array, are entered into
a new array, D, until the CFVsare full. Thus, if a CFV has 100 elements D has 100
rows and N columns, and each column contains the indices of the CFV in a 3D array.
The numberof surviving FSUsfor each of these indices in the ’FSU array’ are collected
and the total numberin each column is entered into a vector, E. These values are the
numberof surviving FSUs in each CFV.
With the methodology described above contiguity of the CFV is not guaranteed
since in some cases the normal-tissue elements closest to a CFV centre might be split
into more than one contiguous object due to a GTV or an irregularly shaped organ,
as illustrated in figure 4.3. Since the outcome (complication or no complication) only
depends on the CFV with the lowest numberof surviving FSUsit is enough to check
that this CFV is contiguous. The centre of this CFV is called CFVCyin.
A binary 3D array, F, is created representing the critical CFV; the indices in the 3D
array belonging to the CFV around CFVCwmin are found in the corresponding column in
D. Functions from Matlab’s image processing toolbox are used to identify the number
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 Figure 4.3: Illustration of a non-contiguous CFV (green area) divided by a GTV (red
area).
of objects in F and the eventual elements belonging to smaller separate objects. For
these elements the values of the distance in C are increased, similarly to how the
GTV elements were penalised, and new values are chosen for this CFV into D and
E subsequently. This procedure is repeated until the CFV is contiguous and then,
since this CFV might not have the lowest FSU survival anymore, E is searched for the
current critical CFV andits contiguity is evaluated. This procedure is repeated until
the CFV with the lowest FSU survival is contiguous. It is not likely that any other
CFV,currently non-contiguous, would have a lower FSU survival if contiguous, since
when forcing a CFV to be contiguous elements are generally moved from close to the
GTVto the periphery of the CFV where the doseis lower.
Finally the outcomeis given by comparing the numberof surviving FSUsin the
critical CFV with the chosen value of FSUmin and the output of the modelis given as
zero or 1, for no complication or complication respectively.
4.3.4 Dose distributions
The dose distributions used in the analyses were generated separately in Matlab. Each
‘patient’ had a different dose distribution and the choice of characteristics for the dose
distribution sets were an important part of each study design.
49
Dose distributions were generated using a simple beam model with the parameters
randomly sampled to make each dose distribution different. Uniform, parallel beams
were created with central-axis dose taken from Jordan [110] for a 6 MV beam, and
a penumbra based on clinical measurements. Scatter was represented by a uniform
low background dose. Figure 4.4 showsslices of three dose distributions generated to
represent lung tumour treatments, using three beams.  
Figure 4.4: Slices of three typical dose distributions generated to represent lung tumour
treatments. The PTV (black line) was defined by the isodose at 90% of the maximum
dose, and the GTV to PTV margin was one voxel wide.
For organs including a target a GTV at the intersection of the beams was excluded
from the surrounding normaltissue in the analysis. This was done by defining the PTV
as the voxels included by the isodose at 90% of the maximum dose, and assuming a
margin of one voxel between PTV and GTV, the GTV was defined as the voxels in
the PTV which were not on the PTV surface; see figure 4.4. Thus the normal-tissue
volume was defined by the dose distribution and the geometry of the PTV, causing
further random inter-patient variation in the normal-tissue dose distribution.
Rather than attempting to closely reproducea typical clinical setup, the purpose of
this approach was to produce representative normal-tissue dose distributions. If the
conventional 95% isodose had been used to define the PTV,large volumes of normal
tissue would have received very high doses, due to the slow fall-off of dose of the simple
three-beam arrangement chosen for lung. The inhomogeneousdose in the GTV was not
a problem since only the normal-tissue dose distribution was used in the simulations.
The PTV was not used for any other purpose thanto define the GTV,andthis procedure
was chosen in order to increase the randomnessandvariation in the normal-tissue dose
distribution, from patient to patient. Thus the small GTV to PTV margin of ~ 3 mm
was of no consequence.
50
4.4 Discussion
The 3D model used to simulate data in this work is inevitably simplistic but attempts
to incorporate the current understanding of how normal tissues/organs respond to
irradiation. It has a unique potential to explore the effect of different factors on the
complication probability for an organ whose response to irradiation has both a local
and a global component, and it takes into account the spatial variation in dose, unlike
currently used DVH-based NTCP models. Therefore, though it is not a complete model
of organ responseto irradiation, this model can be useful for testing the behaviour
of existing NTCP models (see chapter 7). For appropriate analyses, it can generate
pseudo-clinical data without limitations of patient numbersor prescribed dose ranges.
The CFV concept used in this model is similar to the critical volume tolerance
suggested by Roach et al [70] and the variable critical volume model developed by
Bontaet al [71], and also to some extent to the ‘compartment’ considered by Wolbarst et
al. [111]. Considering an organ subregion of contiguous FSUs seemsa naturalchoice,
especially for structural radiation damage(e.g. in skin, rectum [26]) where the loss of a
few contiguous FSUs might reasonably be expected to give a higher risk of complication
than damaging randomly scattered FSUs, and the local ‘FSU density’ might be a critical
parameter {112]. This is supported by the fact that the shape of the dose distribution
is important for late rectal toxicity [113]. The CFV concept is also supported by the
response of mouselungto irradiation, where the tissue in sections of the lungis either
largely undamaged, or completely damaged if a large enough portion of the FSUs have
been destroyed by radiation [52].
Other methods of accounting for the contiguity/connectivity of damaged FSUs have
been suggested by Stavreva et al [65] and Thameset al [67]. In their ‘contiguous
damage’ model Stavreva et al assumed that injury to the spinal cord occurs if the
number of damaged fibres exceeds a threshold, andfor a fibre to be damaged a number
of consecutive FSUs must be inactivated. Thus the spatial distribution of the damaged
FSUs is important in their model. Similarly, the more general cluster model used
by Thameset al, assumes that a complication occursif the size of the largest cluster
of contiguously inactivated FSUs exceeds a threshold. This model can be applied in
one, two or three dimensions. In both of these models the inactivation of FSUsis
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stochastic; in the contiguous damage model the probability of damaging a fibre is
calculated with combinatorial analysis, whilst in the cluster model the maximum cluster
size is determined with computer simulations.
Unlike these models the 3D model does not require inactivated FSUs to be contiguous
(unless FSUmin = 1) to trigger a complication. Rather, it is the overall damage in the
organ specific CFV which is important. The CFVis related to, but not identical with,
the functional reserve. An organ with a large functional reserve has a redundancyof
FSUs andretains its function even if many of them are lost. Thus, the CFV must be
large and FSUmin low, since otherwise a complication is triggered for extensive FSU
loss.
The modelis also based on the FSU concept. Though the characteristics and even
the existence of the FSU are controversial {114, 33], the model is only dependent on
this concept via the assumption that small units of tissue need to be repopulated
through local stem cell division if cells are killed by irradiation. This would still be
valid for tissues which consist of several typesofcells if one type is significantly more
radiosensitive than the others, in which case the integrity of the FSU depends on the
radiosensitivity of the most radiosensitive stem cell. The model could also be extended
to include several FSU populations in one organ (e.g. parenchyma andvessels) which
could respond to dosedistributions in different ways (e.g. in a parallel and serial manner,
respectively); for a discussion see section 1.1.3.
Since the nature of the FSU was not specified when the model was developed,it
is not clear whether an injured stem cell on the edge of an FSU can bereplaced by a
surviving stem cell from a neighbouring FSU. The use of equation 4.1 implies that stem
cells cannot migrate across FSU boundaries. Fenwick and Nahum [115, 31] presented
a formula for NTCP when there are no fixed boundaries between FSUs and showed
that this leads to a higher risk of local damage than if fixed boundaries are assumed.
However, this formula only applies to one-dimensional FSUs. In this thesis the formulas
in section 4.2 will be used.
Thedifference in stem cell radiosensitivity between different organs was represented
by different values of a, whilst keeping a/@ constant, though alternatively 8 could have
been kept constant [116]. The effect of varying a in a population is discussed below.
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One limitation of the model in its current form is that the probability of FSU
inactivation depends on the local dose only, as a direct result of radiation-induced stem
cell depletion. The LQ model and target cell theory do not take account of phenomena
such as low-dose hypersensitivity and the bystander effect; the latter depends on
signalling from surrounding damagedcells [117, 21]. Given appropriate mechanismsfor
these phenomena,their local or non-local effects could be readily incorporated into the
model.
In some cases both the number of stem cells per FSU and the number of FSUs
per voxel were assumed to belarge, resulting in a deterministic local tissue damage
function (equation (4.2)). Otherwise the number of surviving stem cells per FSU or
surviving FSUsper voxel, respectively, were sampled from a binomial distribution, thus
introducing a random element into the local tissue damage function. Whereas for some
dose distributions, associated with a very low or a very high level of tissue damage, the
overall outcome was still deterministic, for others there would then be an element of
randomnessin the induction of a complication for a fixed dose distribution. This is
easily handled by the model unless the FSUis larger than a voxel.
In practice, this model simulates the irradiation of an organ during radiotherapy and
gives the outcomefor the patient in terms of a possible complication for this organ. For
a given dose distribution and FSU distribution, the result is deterministic (except when
NES") and depends on the chosen values of the model parameters. Thereforesampling
the results correspond to what would be observedif a single patient, or a population
of identical patients, could be treated with many different dose distributions. In the
context of a clinical study, however, a spread in radiosensitivity as well as health status
must be accounted for. The inter-patient variation in radiosensitivity and health status
can be represented in the model by sampling the value of a and FSUmin or Neoe
respectively, from an appropriate probability distribution, for each patient.
4.5 Flowchart
Here follows a flowchart illustrating the steps of the simulations described in section 4.3.
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Chapter 5
The Influence of Dataset
Characteristics on Correlations
between Dose and Outcome
In this study simulations are carried out on the model described in chapter 4, to
investigate correlations between various dose-volume parameters and the incidence
of ‘complications’ in order to provide deeper insight into what can be expected of
such analyses in clinical studies. We use the model to address a series of questions,
including: How much information about an organ’s dose-volume response to irradiation
can be extracted from clinical studies? How does the organ architecture influence the
correlation between dose-volume parameters and outcome? Whydodifferent clinical
studies often lead to different conclusions about dose-volume parameters as complication
predictors [118]? This study focuses on the effect of different dose distributions on
correlation analyses since a key feature of this modelis its ability to evaluate the effect
of full 3D dose distributions.
5.1 Dose distributions
The correlations between dose-volume parameters and outcome seem to be influenced
by dose distribution characteristics [75, 68], such as variability in mean or maximum
dose and volumeirradiated. For an organ which encompasses the tumour the maximum
dose varies little from patient to patient and the mean dose dependson theirradiated
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volume. Such organs are often of parallel architecture. For an organ at risk outside
the tumour, on the other hand, the maximum dose can differ greatly from patient to
patient, depending on the distance to the tumour and the numberof beamscrossing the
organ; this is often the case for serial organs. To investigate to what extent such features
influence the correlations observed, the analysis was performed both for ‘lung-type’ and
‘cord-type’ dose distributions, generated as described in section 4.3.4.
For the lung-type dose distributions three beams, perpendicular to different sides of
the cube representing the organ, were made to intersect at a randomly selected point.
For each generated dose distribution, the weights of the three beams and the beam
widths were also randomly sampled. The resulting cumulative DVHs(see figure 5.1(a))
were compared to lung DVHsof lung cancer patients treated at Clatterbridge Centre
for Oncology (3D conformal radiotherapy), in order to achieve a typical range of mean
and maximum dosefor a given prescription dose.
Similarly, the second set of dose distributions was made to resemble the oesophagus
and spinal cord dose distributions for the lung cancer patients mentioned above, without
any tumour in the organ volume(see figure 5.1(b)). The dose distributions were
generated as described above for the lung-type dose distributions, though in this case
also the number of beamscrossing the organ was sampled for each patient (average
1.7). This method of generating dose distributions ensured that the datasets used in
the analysis were not limited in size or variation butstill clinically relevant.
100 100(a)  0 20 40 60 80 100 120 0 20 40 60 80 100 120
Dose (%) Dose (%)
Figure 5.1: Fifty sampled dose distributions used to resemble (a) lung DVHsand (b)
spinal cord and oesophagus DVHs,during lung tumour treatments.
58
5.2 3D model input data
The different organ types were represented by different sizes of the CFV: 0.75 for a
parallel organ, 0.10 for a semi-parallel organ and 1.0 x 10~* for a serial organ. The serial
organ was represented by a very small CFV in order to guarantee typical serial-organ
behaviour where the maximum dose is important. If the CFV had been a cubetheside
of the cube would have been 45, 23 and 2 voxels, respectively, covering the full range in
the cube of 50 x 50 x 50 voxels representing the organ. However, the shape of the CFV
was not restricted to a cube but rather to a sphere which could adapt its shape around
organ and tumoursurfaces.
The value of FSUmin = 0.56 was kept constant; a value in the middle of its allowed
range (0-1) was considered reasonable since organs seem to function despite certain
tissue damage. Also, this value resulted in low numbers of complications in theclinically
relevant dose range for plausible values of a and Nee.
For the parallel-type organ, the value of a was chosen so that, with the lung-type
dose distributions, 10% of the patient cohort with a prescription dose of 55 Gy/20
fractions experienced a complication, in line with clinical experience at Clatterbridge
Centre for Oncology. For the other organ types (represented by smaller sizes of the CFV),
a@ was chosen so that a complication rate of 50% was reached at the same prescription
dose as for the parallel-type organ, in order to facilitate comparison between the organ
types. These values were 0.260 Gy~!, 0.137 Gy~! and 0.0382 Gy~! for the parallel,
semi-parallel and serial organ, respectively. Although this last value might seem very low,
similar values have been considered for normaltissues {119, 120, 121]. Alternatively, Ns.
or FSUmin could have been adjusted and a remainedfixed for the different organ types,
but Ns has a much weakerinfluence on the response, and FSUmin sometimes too strong.
The values of a listed above were also used with the cord-type dose distributions, in
which case a 50% complication rate was reached at different prescription doses due to
different volume effects responding differently to the different sets of dose distributions
in figure 5.1.
A generic late responding normal-tissue value of a/3 = 3 Gy was used, and for the
numberof stem cells in an FSU, Ngc, a value of 120 was chosen based on estimates of
the numberof stem cells in an alveolus in the lung [122].
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5.3. Simulation of clinical data
In this chapter the model described in chapter 4 was used to simulate a clinical study
by calculating outcomefor cohorts of patients at eight different prescription doses, and
correlating calculated dose-volume parameters with the outcomeusinglogistic regression
with SPSS 16 (SPSS Inc.). This was performedfor different sizes of the CFV to illustrate
the cases of serial, semi-parallel and parallel tissue architectures as described above.
The number offractions was 20 in all simulations and the set of eight prescription
doses was chosen to give a range of complication rates from 1% to 50% (figure 5.2). Since
the response pattern was different for each organ type, the sets of prescription doses were
different and ranged from 0.75 to 5.8 Gy perfraction. This latter very high prescription
dose was only necessary for the serial organ- and cord-type dose distributions because the
mean maximum dose (in the organ) was 60% of the prescription dose, and because of the
choice of model parameters (see section 5.2). The dose distributions were transformed
into 2 Gy equivalent doses (EQD2,see section 1.1.1), using a/6 = 3 Gy.
The dose-volume parameters included were prescription dose, maximum dose, mean
dose, Vag and Lyman-Kutcher-Burman (LKB) NTCP (section 2.1.1). The LKB model
parameters were fitted to each organ architecture dataset separately with the maximum
likelihood method (section 3.1.1). Each dataset included eight cohorts consisting of 100
synthetic dose distributions (as described in section 5.1), representing the patients in
the cohort, and the outcomes werepredicted by the 3D model.
5.4 Correlation analysis
A logistic regression analysis was carried out for correlations between individual dose-
volume parameters and outcome,i.e. complication frequency, generated by the 3D model.
The strengths of these correlations are presented in table 5.1, where the Nagelkerke R?
parameter estimates how much ofthe variance in the outcome can beexplained bythis
model fit (section 3.3.4). Thus a high R? value indicates a strong correlation of the
dose-volume parameter of interest with the outcome.
The results in table 5.1 show that the outcomecorrelated well with maximum dose
for organs with small CFV,as expected; for the intermediate CFV (semi-parallel organ)
it correlated with mean dose, V29 and LKB NTCP;and for large CFV with mean dose,
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Figure 5.2: Simulated outcome data used in the correlation analysis. The stars, wedges
and circles are for the parallel, semi-parallel and serial organ, respectively. (a) The
radiosensitivity parameter a was adjusted to normalize the dose-response curves at 50%
complication rate with lung-type dose distributions (see figure 5.1(a)). (b) Keeping the
3D model parameter values fixed, the serial organ tolerated higher prescription doses
than the other organs with spinal cord-type dose distributions(see figure 5.1(b)). These
curves appear to be saturating due to the large range in dose distributions in terms of
maximum dose, so that some need a very muchhigher prescription dose than others to
cause a complication.
LKB NTCPand Va. This is in line with the clinical experience of maximum dose
being a good predictor for spinal cord toxicity, which is often classified as a series-type
complication, and mean dose and V4 correlating strongly with the outcome for the
parallel-type complication radiation pneumonitis [118, 123]. Our results indicate that
none of the considered dose-volume parametersis a perfect predictor of the outcome
(R? = 1), even though no population variation in radiosensitivity or health status has
been assumed here. These confounding factors can be expected to make the observed
correlations weaker.
5.5 Correlations for different V,
This analysis was also carried out for the parameter V; (the volumereceiving at least
x Gy), with a range of cut-off doses x. This is often done to find the volume parameter
which is the best complication predictor, and based on the result conclusions are
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Table 5.1: The Nagelkerke R? for a logistic regression analysis for each dose-volume
parameter separately, with lung-type dose distributions.
 
 
Organ type
Dose-volume parameter Parallel Semi-parallel Serial
Prescription dose 0.18 0.15 0.22
Maximum dose 0.11 0.13 0.91
Mean dose 0.88 0.49 0.01
V20 0.47 0.47 0.08
LKB NTCP 0.72> —0.41° 0.334
 
“py = 0.07; all other p-values < 0.001.
/TDso = 13.8 Gy, m = 0.089, n = 1.15.
°TDso = 10.6 Gy, m = 0.25, n = 1.90.
4TDs9 = 73.1 Gy, m = 0.047, n = 0.035.
sometimes drawn concerning the volumeeffect and tissue architecture.
Thus far a range of prescription doses had been used since otherwise an eventual
correlation between maximum dose and outcomecould have been obscured because of a
low ‘statistical resolution’. On the other hand, in the following analysis the influence
of dose distribution characteristics was clearer without the variation in prescription
dose. Therefore, rather than using the data for eight prescription doses, here the 800
dose distributions were given at a single prescription dose in the simulations. The
prescription dose, 3.25 Gy x 20, was chosen to give a complication rate of around 50%.
Figure 5.3(a) shows how strongly V; is correlated with the outcome for different values
of x. To determine whether these correlations are due to the volumeeffect of the organ
or to the characteristics of the dose distributions in the study, the spread in the Vz,
values in the dataset was studied. Figure 5.3(b) shows the standard deviation in V;
amongst the dose distributions, as a function of z.
Though the strength of correlation is not necessarily expected to follow the shape of
the standard deviation curve, a small variance in a dose-volume parameteris expected
to give a lower statistical resolution so that the rank order of the patients is easily
disturbed by other factors influencing the observed correlations.
Typically there is a high level of cross-correlation amongst the dose-volume parame-
ters, which can also influence the apparent correlations with outcome. Figure 5.4 shows
the Spearmancorrelation coefficient for the range of the V, parametersin figure 5.3,
as well as for the maximum dose and mean dosesince these correlate strongly with
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Figure 5.3: (a) Strength of correlation between V, and outcomefor different cut-off doses
x. (b) The standard deviation in V; in the set of 800 dose distributions for different z,
in percent of the normal-tissue volume. The dashes, diamonds andcircles are for the
parallel, semi-parallel and serial organ, respectively.
outcomefor serial versus parallel organs. The V, parameters which correlate strongly
with these are also expected to show strong correlations with outcome. Since the same
dose distributions were used forall organ types, figure 5.3(b) and figure 5.4 were the
same for all three datasets, whilst the correlation in figure 5.3(a) depended on the
outcome and was different for each organ type.
A comparison of figures 5.3(b) and 5.4 with figure 5.3(a) indicates that for the
parallel organ the cross-correlation of the V, parameters with the mean dose explains
the observed strengths of correlation, since the mean dose correlates strongly with
outcome. Similarly, for the serial organ, the V; parameters which correlate strongly with
the maximum dosealso correlate with outcome. As the outcome for the semi-parallel
organ does not correlate strongly with the mean or the maximum dose, the curve shown
in figure 5.3(a) cannot be explained by any cross-correlation with these parameters.
Instead it largely follows the standard deviation curve shownin figure 5.3(b), except that
Vo25 seems more important and V5 and Vjo less important. This is partly explained by a
cross-correlation of Vj5-Va5 with Djo-D29 which were found to correlate with outcome.
This issue is further discussed below. The similarity between the curves infigures 5.3(a)
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Figure 5.4: Spearman correlation coefficient for cross-correlation between dose-volume
parameters (1V = maximum dose, m = mean dose).
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and (b) for the semi-parallel organ could mean that no V, parameter in particular is
important for this organ, so that a low standard deviation obscures the low level of
correlation whilst it is boosted where the standard deviation is high.
5.6 Correlations for different D,
Further, the correlation between D, and outcomefor different cut-off volumes x was
investigated (figure 5.5(a)), as well as the corresponding spread in D,; values in the
dataset for the different cut-off values x (figure 5.5(b)). Dz is the lowest dose given to
the hottest 7% of the organ. This is a convenient parametersince, like Vz, it can be read
straight off a cumulative DVH.It can also conceptually be linked to the CFV parameter
considering that the dose to the hottest contiguous volume influences the response of
the 3D model. Thus Do.91%, Dio and D75 might be expected to be good predictors for
the serial, semi-parallel and parallel organ, respectively, though not perfectly so, since
the FSU kill in a CFV only relates indirectly to the minimum dose to this volume, and
the D, parameter does not necessarily correspond to a contiguous volume. Figure 5.6
shows the Spearman correlation coefficient for the range of D, parameters in figure 5.5,
as well as for the maximum dose and mean dose.
As in the case of Vz, the strong correlation of maximum dose and that of mean dose
with the outcome, and their cross-correlation with the D,; parameters, explain the shape
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Figure 5.5: (a) Strength of correlation between D,; and outcomefor different cut-off
volumes x. (b) The standard deviation in D, in the set of 800 dose distributions for
different x. The dashes, diamonds and circles are for the parallel, semi-parallel and
serial organ, respectively.
of the correlation curve in figure 5.5(a) for the serial and parallel organ, respectively,
as is evident from a comparison with figure 5.6. The D, parameter which correlates
the most strongly with the outcome for the semi-parallel organ is Dig. Since thereis
cross-correlation between Dj9 and Dj5-D39, these also correlate rather strongly with
the outcome, and around D4; there is a slight peak corresponding to the increase in the
D, standard deviation at D4;.
As expected the dose received by the hottest 10% of the organ was important for the
semi-parallel organ since the CFV was 10% for these simulations. Indeed, here the D;
correlation analysis has picked up something which is due to the inherent organ function
(in this case the 3D model volumeeffect). This also explains the correlation between
Vo5 and the outcome (andthe cross-correlation between V25 and Djo), as the average
isodose including the hottest 10% of the organ was between 20 and 25 Gy. Similarly,
Do.o1% is importantfor the serial organ (CFV = 1.0 x 10~*), but since the organs were
not irradiated to volumeslarger than 60% with any significant dose, D7; is not found
to be important for the parallel organ (CFV = 0.75).
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Figure 5.6: Spearman correlation coefficient for cross-correlation between dose-volume
parameters (IM = maximum dose, m = mean dose, Do = Do.01%).
5.7 The influence of dose-distribution characteristics
The correlation analysis was also performed for simulations with dose distributions
resembling oesophagusand spinal cord dose distributions during lung cancer treatments
(as described in section 5.1). Results are presented in table 5.2. In this case no GTV
was extracted from the normal tissue since these organs at risk are assumed to be
uninvolved by any tumour. Thus the high-dose volumeis generally contiguous and
regular in shape unlike the lung-type dose-distribution case. This, together with a
larger variance in maximum dose, explains the stronger correlations of the outcome with
maximum dose, since with similar dose distributions the dose to the CFV placed around
the maximum dose (which in this case generally will be the critical CFV) will scale
roughly with the maximum dose. This is not necessarily the case with an irregularly
shaped high-dose region (e.g. caused by an extracted GTV)since the critical CFV will
be placed around the maximum doseless consistently. Similarly the mean dose will
scale with the maximum dose more consistently for uninvolved organs at risk, which
explains the high correlation with mean dosefor the serial organ in table 5.2.
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Table 5.2: The Nagelkerke R? for a logistic regression analysis* for each dose-volume
parameter separately, with spinal cord-type dose distributions.
 
 Organ type
Dose-volume parameter Parallel Semi-parallel Serial
Prescription dose 0.16 0.14 0.14
Maximum dose 0.35 0.63 0.98
Mean dose 0.80 0.63 0.47
Vo20 0.46 0.77 0.12
LKB NTCP 0.72 —-0..82° 0.964
 
*All p-values < 0.001.
bTDso = 8.3 Gy, m = 0.32, n = 0.98.
°TDs = 17 Gy, m = 0.17, n = 0.25.
ITDs = 76 Gy, m = 0.027, n = 0.011.
For the semi-parallel and serial organs, the correlation between the LKB NTCP
prediction and outcome is muchhigher for the cord-type dose distributions than for the
lung-type dose distributions. As shown in table 1 the LKB NTCP model, which is based
on the DVHs,hasdifficulties in fitting to the complications generated when the high-dose
region is non-contiguous, i.e. when a GT'Vis extracted from the normal-tissue volume.
In most cases the serial organs are uninvolved organs at risk, corresponding to the
cord-type dose distribution, which should makeit easier to fit the LKB modeltoclinical
serial-type complication data, if indeed the spatial distribution of FSU inactivation is
important.
For parallel organs, on the other hand, the spatial distribution of FSU inactivation
has a smaller effect since in this case virtually all high-dose voxels are included in every
CFV. This also means that the outcome was determined by the volumes receiving the
lowest doses, which varied more from patient to patient for cord-type dose distributions
than for the lung-type ones where the background dose due to scatter was comparatively
constant. This dependence on the low-dose volume for the lung-type dose distributions
is reflected in the value of n greater than unity for parallel and semi-parallel organs.
5.8 Inter-patient variation in radiosensitivity
The above results were based on simulations using fixed parameter values, since the focus
of this study was on the influence of dose-distribution characteristics on the correlations
observed in a clinical study. In order to estimate the effect of an inter-patient variability
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in radiosensitivity, the analysis with the lung-type dose distributions was repeated on
data simulated with the value of a randomly sampled from a log-normal probability
density function with a standard deviation of 25%. This large standard deviation was
chosen in order to accentuate the effect on a correlation analysis.
For each organ type a thousand treatments with different dose distributions and
with different values of a were simulated at each prescription dose, in order to establish
confidence intervals for the dose-response curves. Figure 5.7 shows the results of the
simulations, with and without variation in radiosensitivity.
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Figure 5.7: Simulated outcome data for lung-type dose distributions, with (line and
errorbars) and without (only symbols) inter-patient variation in radiosensitivity. The
stars, wedges andcircles are for the parallel, semi-parallel and serial organ, respectively.
The data points without variation in radiosensitivity are the same as in figure 5.2. The
confidence intervals for the data with sampled radiosensitivity are for one binomial
standard deviation based on 1000 ’patients’ per prescription dose, each patient with a
different dose distribution.
The steepness of the dose-responsecurvefor the serial organ was reduced considerably
by introducing the variation in inter-patient radiosensitivity, as expected, andless for the
parallel and semi-parallel organs. As there was a great inter-patient variability in mean
dose for any prescription dose dueto the different lung-type dose distributions, the slope
for the parallel organ was already rather shallow and this seems to have a higher impact
than the added radiosensitivity variability. The inter-patient variability in maximum
dose, on the other hand, is limited and the added radiosensitivity variability has a
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significant effect for the serial organ, where the maximumdoseis strongly correlated
with outcome. Therefore the influence of inter-patient radiosensitivity variability on the
population averaged NTCP depends on the normal-tissue dose distributions as well as
on the organ architecture.
This is analogous to the influence of an inter-tumour variation in radiosensitivity on
the population averaged tumour control probability, which is usually large since the
dose most often is uniform and constant from patient to patient. However, the effect of
a variation in radiosensitivity on the correlation between a dose metric and outcome is
likely to be smaller for NTCP than for TCP, especially in the case of a parallel organ,
since for organs at risk there is generally a variation in response due to the variation in
dose distribution from patient to patient, in contrast to the usually homogeneous dose
to the tumour.
Table 5.3 shows the strengths of the correlations between dose-volume parameters
and the complication rate when the inter-patient variation in radiosensitivity is taken
into account. This analysis was based on 100 treatments randomly chosen from each
prescription dose in order to be comparable to the values in table 5.1.
Table 5.3: The Nagelkerke R? for a logistic regression analysis for each dose-volume
parameter separately, with lung-type dose distributions and inter-patient variation in
radiosensitivity.
 
 
 
Organ type
Dose-volume parameter Parallel Semi-parallel Serial
Prescription dose 0.069 0.23 0.013
Maximum dose 0.051 0.20 0.43
Mean dose 0.28 0.32 0.0007
V20 0.18 0.23 0.001
LKB NTCP 0.25° 0.27" 0.0324
*p > 0.05
bTDs = 15 Gy, m = 0.23, n = 1.0.
°TDs = 19 Gy, m = 0.36, n = 0.71.
ITDs9 = 73 Gy, m = 0.023, n = 0.040.
The overall effect of introducing the variation in a was to weaken the correlations
between dose-volume parameters and the complication rate, as expected. This had
the greatest impact on the serial organ, for which even the maximum dose now only
correlated weakly with the complication rate. With clinical data the maximum doseis
generally found to be a goodpredictor of the complication rate for serial organs, which
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could be due to the typically much larger spread in maximum dosefor serial organs at
risk, and/or a smaller natural variation in radiosensitivity than is assumed in this study.
The actual values in table 5.3 are only indicative since the standard deviation in a
might be less than 25% for a clinical dataset. However, this analysis shows weakenedcor-
relations between dose-volume parameters and outcome whenan inter-patient variation
in radiosensitivity is introduced, and therefore the strengths of correlations observed in
clinical studies are likely to be lower than those in table 5.1. This indicates that simple
dose-volume parameters are inadequate as complication predictors for most organs,
except the maximum dosefor serial organs. As pointed out by Konget al [118],‘a
statistically significant association or description of complication rates for populations of
patients is not the same thing as a goodpredictor of toxicity for an individual patient’.
It is difficult to compare the strengths of correlation observed in this study with
clinical dose-volume studies as generally only the p-value is reported [123].
5.9 Conclusions
A 3D model of normal-tissue response to irradiation was constructed which simulates
pseudo-clinical outcome data for arbitrary dose distributions. Such simulations are ideal
for studying data-analysis methodology, given the flexibility of the model and that simu-
lations are easily performed in large numbers. Furthermore it was shown that results can
be generated to resembleclinical studies, in terms of dose-volume parameterscorrelating
with the outcome for conformal radiotherapy-like dose distributions (table 5.1).
The study of the correlations between V, and outcome for different values of dose,
x, showed that the detection of strong correlations is dependent both on the tissue
architecture and to a certain extent on the characteristics of the set of dose distributions
in the study, as seen for the semi-parallel organ. Moreover, if the outcomecorrelates
strongly with maximum or mean dose,cross-correlation with this parameter will greatly
influence the correlation between outcome and V,. It is interesting that the volume, z,
for which the D; parameter correlated the strongest with outcomefor the serial and
semi-parallel organs, corresponded to the size of the CFV. This indicates that some
information of the volume effect of an organ can be gained from correlation analysis,
if care is taken to identify other factors influencing the observedcorrelations.
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This work may help investigators interpret the results from clinical studies and
indicates how to study the influence of dataset characteristics on their results.
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Chapter 6
The Radiobiological Knowledge
Base for Mechanistic NTCP
Modelling
6.1 Introduction
Since the mechanisms behind radiation-induced normal-tissue injury are not fully
understood, predictive mechanistic NTCP modelling is not yet feasible (see section 2.3.1).
However, a mechanistic NTCP model can be used as a framework for summarising the
current radiobiological knowledge base, and for generating hypotheses about radiation-
induced normal-tissue effects [124]. In this chapter, relevant information is collected
from the literature for two important organs at risk, lung and rectum, and used to
derive plausible parameter values for the 3D model described in chapter 4. It is hoped
that this work will increase our understanding of normal-tissue effects, and highlight
some areas that need further research before a full understanding of radiation-induced
pathogenesis can lead to predictive mechanistic modelling of NTCP.
Importantly, normal-tissue effects will be considered from a mechanistic, rather than
descriptive, point of view. This will be done by a reductionistic approach, where local
effects on tissues (FSU inactivation), and loss of global organ function, are identified as
different levels of radiation injury. The mechanisms by which the latter depends on the
former vary between organs.
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6.2 Pathogenesis of radiation side-effects
Radiation side-effects can be either acute (early) or chronic (late); the operational cut-off
time between these phases has been set at three months after start of treatment [125].
However,in this chapter it will be more useful to distinguish between these effects based
on their pathogenesis rather than on when they occur[126].
Acute effects typically result from depletion of epithelial/parenchymalcells, but are
also associated with an inflammatory response [125]. For tissues with short turnover
time this might happen during treatment (e.g. oesophagitis), whilst it occurs later for
tissues with long turnover time (e.g. radiation pneumonitis) [126]. The ability of the
tissue to recover from this damage dependsontheproliferation capacity and mobility
of the stem cell population.
Chronic effects, on the other hand, have a much more complex pathogenesis, including
interactions between changes to the parenchyma, direct damage to the stroma and
vasculature, and immunologic responses of the tissue [19]. The most commonchronic
effect is fibrosis, which develops months to years after radiotherapy, in most tissues.
Fibrosis is predominantly a stromal lesion caused by excessive collagen deposition as
a part of a wound-healing process [127, 24]. Damage to the microvasculture is also
important for chronic effects due to the slow turnover of the endothelial cells, and its
close connection to tissue homeostasis [19]. Loss of microvasculature also leads to direct
tissue damage through ischemia [24], which can cause necrosis and ulcers. Furthermore,
there appears to be a strong connection between injury to the microvasculature and
radiation fibrosis [128, 13, 129].
Some organs have both an acute and a chronic phase, whilst for other organs one
or the other is predominant [19]. For some organs the two phases can bedifficult to
separate.
6.3. Lung
The lung is a commonorgan at risk during thoracic irradiation and often sets the limit
for local tumourcontrol of lung cancer [130]. Since lung cancer is the cancer type with
the highest mortality rate [131], it is imperative to understand how the lung responds
to dose distributions, in order not to limit the dose to the tumour unnecessarily.
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6.3.1 Radiation-induced lung toxicity
Irradiation of the lungs can lead to radiation pneumonitis (RP), which usually develops
around 4-6 weeks after treatment [125]. This acute effect usually causes symptoms
like mild fever, dyspnea and cough, andif not too severe, or if treated with steroids,
resolves without chronic symptoms. During RP many type I pneumocytes, which line
the alveolar surface, are lost, and the stem cells of the pulmonary epithelium, the type
II pneumocytes, show an increased rate of proliferation, migrate to denuded areas and
some differentiate into type I pneumocytes to replace the damaged cells. RP is also
characterised by an inflammatory response [132, 10].
Chronic radiation fibrosis can develop within 1-2 years after treatment. Deposition of
collagen leads to interstitial fibrosis with thickening alveolar septa, a smaller active lung
volumeandless efficient gas transfer. The patient might experience dyspnea, especially
on exertion. Damage to pneumocytes, fibroblasts, the microvascular endothelium and
the extracellular matrix are all important for the development of radiation fibrosis.
However, relatively severe local damage is required to set off the fibrotic response.
As long as the extracellular matrix is intact, lung tissue can be restored by type II
pneumocytes, but if the internal structure is lost, tissue repair with scar formation
follows, which is the initial phase of fibrosis [23, 132, 19].
In this thesis only RP will be modelled, and thoughthis is an acute normal-tissue
effect, associated with depletion of parenchymalcells, the turnover of the pneumocytes
is slow enoughfor timeeffects to be negligible, and generally symptoms do not appear
before the end of treatment.
The shape of the lung was not considered crucial to the results of simulations, and
therefore the full array, excluding the GTV,was chosen to represent the total paired
lung volume;see figure 6.1.
6.3.2 Modelling local tissue damage
Dose response of the FSU
Ona locallevel, tissue damage is modelled by inactivation of FSUs in the 3D model.
Each FSU respondsindependently to irradiation, and thus only the local dose (not
the volumeirradiated) influences the survival probability of an individual FSU. The
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 Figure 6.1: Geometrical representation of a pair of lungs in the model. The blue volume
is normal lung tissue, and the purple volume is the GTV,which is not included in the
normal lung.
dose-responseof a tissue therefore depends on the numberof stem cells per FSU (Nec)
and the radiosensitivity of these stem cells (a). The radiosensitivity may vary between
patients, and since generally only population based data are available it is reasonable to
consider the average radiosensitivity, a. If the threshold dose for FSU inactivation is
known,an iso-effect relationship between @ and Ng; is given by the equation for the
probability of FSU inactivation (see equations 1.2 and 4.1):
—andad—pn 2Ppgu = eNero one on (6.1)
This relationship is shown in figure 6.2, for the threshold dose estimated as 8.4 Gy (see
below). Importantly, this shows the range of possible numbers of stem cells per FSU,
given the plausible range for @; see below.
The threshold dose of 8.4 Gy was estimated based on the results of a study by
Gopalet al. [133], where thelossof diffusion capacity in the lung was related to the local
dose. Here 8.4 Gy is the lowest total dose, normalised to 2-Gy fractions (a/6 = 3 Gy),
for which a local tissue effect was detected. Although this was a study on only 26
patients, the 95% confidence interval for the threshold dose was small (7.0-9.8). Still,
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Figure 6.2: Values of & and N,, resulting in 90% FSU survival for 8.4 Gy. The expected
range of a, and the combinations of @ and Ng, associated with the alveolus and acinus
as FSU, respectively, are indicated; see section below about the FSU of radiation
pneumonitis.
this value should be considered approximate since it is based on a modelrelating global
lung function to the local dose, rather than measurements of the actual local effect.
Despite this drawback the loss of diffusion capacity seems to be the most relevant
measure of the local effect of radiation, since it measures the actual gas exchangein
the lungs [133]. For other endpoints, studies on local lung function in termsofloss of
perfusion could be useful. In contrast, these suggest a much higher dose threshold for
tissue damage, with continuously increasing damage up to 60 Gy [134, 135, 136] (c.f.
figure 6.3).
The fact that most of the patients in the study by Gopalet al. [133] also received
chemotherapy is another important source of uncertainty in the chosen threshold dose.
In manystudies on 3D conformal radiotherapy for lung tumours the volumereceiving at
least 20 Gy (V29) has been associated with RP [118], which suggests that the lower dose
found in Gopal’s study could be due to a sensitising effect of the chemotherapy. However,
such findings are most likely treatment technique dependent [107, 137], and whether the
lower dose threshold (V5) indicated by recent studies, on data from IMRT for mesothe-
lioma [138] and 3D conformal radiotherapy for oesophagus cancer [139], is a result of the
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different radiotherapy treatment technique, or the influence of chemotherapy/surgery,is
not clear.
Therefore, until more reliable data for the threshold dose associated with local loss of
diffusion capacity is available, it will be assumed to be 8.4 Gy. However, such low doses
can only cause a low level of FSU inactivation, and only contribute to the complication
probability in addition to volumes at higher dose [79]. Also, since up to 13 Gy total
lung irradiation is tolerated by somepatients [140], the slope of the dose-response curve
for the FSU cannot be too steep.
Figure 6.3 shows this dose-response for one combination of parameter values from
figure 6.2: @ = 0.24 Gy! and Nsc = 67. This combination gives 90% FSU survival at
8.4 Gy, and a slope shallow enoughto allow for some FSU survival even at 13 Gy, which
agrees with the experience from total lung irradiation mentioned above. The slope of
this curve is also in line with the local dose-response reported by Gopal et al. [133]
where regions of < 6.3 Gy3, 6.3-13.4 Gy3 and > 13.4 Gy3 (EQD2) were associated with
a 0%, 70% and 90% decrease in diffusion capacity respectively.
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Figure 6.3: Median FSU survival with 5 and 95% quantiles for different local doses;
Nec = 67, & = 0.24 Gy! and og = 15%. The position and slope of the curve have been
guided by the threshold dosefor local loss of diffusion capacity, and the dose limit for
total lung irradiation.
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The range of FSU survival shown for each dose in figure 6.3 is based on calculations
for 1000 ‘patients’, where the radiosensitivity for each patient is sampled from a log-
normal distribution with mean 0.24 Gy"! and a standard deviation of 15% (assuming a
fixed Ns- = 67). Interestingly, these results indicate a large variation in dose-response
of the FSU between patients, even for a moderate variation in radiosensitivity.
Furthermore, this curve displays almost complete FSU inactivation for doses above
25 Gy. This indicates that for the endpoint of radiation pneumonitis maximum local
effect is reached at a relatively low dose. However, the dose effect for other endpoints,
such as fibrosis, may saturate at higher doses, as indicated by the studies on perfusion
mentioned above.
Thereis little data on organ specific normal-tissue radiosensitivity available in the
literature. Two studies report values for the LQ parameters for lung, derived from
radiobiological modelling [121, 141]. Very low values of a were reported (0.03-0.19 Gy");
however, these models did not include any volumeeffect but assumed that normal-tissue
complication probability depended directly on FSU inactivation. Considering the large
volumeeffect of the lung the radiosensitivity is expected to be greater, since a significant
amount of FSUs must be inactivated before symptoms are observed. As expected,
modelling including a volume effect, on mouse lung data, resulted in a values between
0.26 and 0.37 Gy? [52].
The FSU of radiation pneumonitis
In the same paper Stavrev et al. advocated the acinus as the FSU of the lung,since
the size of this structure matched the FSUsize predicted by their model, and it seems
anatomically possible for cells to migrate freely throughout the acinus. However, the
acinus of the humanlungis a relatively large structure containing over 10,000 alveoli [142],
with around 67 type II pneumocytes [143] in each; type II pneumocytes are the stem
cells of the pulmonary epithelium [144, 142]. This means that the acinus contains over
half a million stem cells, which according to figure 6.2 leads to an unreasonably high
value of a.
Timmerman etal. [36] on the other hand suggest that stem cells cannot migrate
between alveoli, and conclude that the alveolus is the FSU of the lung. In this case the
value of N,- would be 67 (on the average), and then a 90% FSU survival probability
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at 8.4 Gy would be reached for @ = 0.24 Gy"! (figure 6.2). This value ofa is close to
its expected range. Another indication that the alveolus is the FSU, rather than the
acinus, is given by the dose-response curve for the acinus as the FSU, which would be
much steeper than the one shownin figure 6.3 (for the alveolus as the FSU), and would
have no FSU survival at all at 13 Gy.
Thus, the FSU ofthe lungis identified as the alveolus and the approximate parameter
values associated with local tissue damage are N.- = 67 and @ = 0.24 Gy". The average
numberofalveoli in a normalpair of lungs is 500 million with standard deviation 180
million [145]. In the 125,000 voxel array of the model this means 4,000 FSUsper voxel.
A lower mean FSU density of 3,600 FSUs/voxel was chosen,reflecting the frequent poor
health status amongst lung cancerpatients.
Local tissue damagein the lung is expected to follow the dose response function shown
in figure 6.3. The importance of low doses indicated by these results is in agreement
with the classification of the lung as one of the most radiosensitive tissues [125]. To be
able to explain why much higher doses are frequently administered to the lung without
causing clinical symptoms, the link between local tissue damage and theloss of global
organ function must be investigated.
6.3.3. Modelling loss of global organ function
In the 3D modeltheloss of global organ function is determined by thecritical functioning
volume (CFV), as well as the distribution of surviving FSUs. A complication is triggered
only if the number of FSUsfalls below FSUmin in any one CFV. Thesize of the CFV
is related to the functional reserve (redundancy of FSUs) and the volumeeffect of the
organ (section 1.1.2).
The ultimate function of the lung is gas exchange, which is dependent on a sufficient
numberof functioning alveoli [27]. As such the CFV could be expected to encompass
the total volume of the organ, and FSUmin might be given by the total lung volume
minus the functional reserve!. However,there is evidence of more complex volumeeffect
mechanisms in the lung.
With their mouse model Stavrev et al. [52] found that at low doses a portion of the
FSUs were injured and recovered independently of each other, with the damaged FSUs
 
1FSUmin is the fraction of surviving FSUs each CFV needsin order to avoid a complication, whilst the
functional reserve is the fraction of the organ volume which can be lost without causing a complication.
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randomly distributed within the irradiated volume. In contrast, above a threshold of
tissue damage(i.e. local dose) all the FSUsin a surrounding subvolumeof the lung
were inactivated, and therefore no surviving FSUs occurred randomly in the volume.
This additional tissue damage throughout a contiguous region might be the result
of an inflammatory process, triggered by the initial radiation-induced tissue damage.
Thus, the radiation-induced tissue damagein itself might not have caused significant
loss of organ function, but since it also triggers inflammation-induced tissue damage a
complication occurred. In this case the CFV represents the large volume over which this
inflammation-induced damage spreads, after the radiation-induced damage has caused
the numberof functioning FSUs in the volumeto fall below FSUin.
These volumes are illustrated in figure 6.4, where for simplicity partial uniform
irradiation is assumed (only A irradiated); A is the volumeirradiated and damaged,
B is the volume damagedindirectly (e.g. through inflammation) by the irradiation of
volume A, and C is the (unirradiated and) undamaged volume. The CFV corresponds
to the volume A+B, and FSUmin to B.
 
 
Figure 6.4: Illustration of the application of the CFV concept to the lung. A = irradiated
volume, B = unirradiated but damaged volume, C = unirradiated and undamaged
volume.
Based on the size of the smallest damaged volume causing a complication in the
mouse [52], the size of the CFV was approximated to be 75% of the total lung volume.
Simulations with the model were then carried out for different values of FSUmin. One
hundred lung-type dose distributions were delivered at a prescription dose resulting in
an average mean lung dose of 29 Gy, which corresponds to the EUD expectedto give
50% complication probability, based on the LKB model fitted to clinical data [93]. This
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prescription dose was 7 Gy x 20 for the dose distributions of the dataset. Simulations
were repeated for different values of FSUmin, until 50% complication rate was achieved,
between 0.46 and 0.47.
Theplausibility of this value is confirmed by the volume which must be spared
from radiation damage, in order to avoid pulmonary complications, suggested by a
correlation analysis for a threshold dose of 5 Gy [75]. The value of around 60% of the
lung volume? from this study corresponds? to FSUmin = 0.47. However, the patients in
this study were treated with chemoradiotherapy, and a much lower value of around 0.11
is suggested by a large study by Seppenwoolde et al. [43], where it was found that 33%
of the total lung volume must be spared from doses above 13 Gy.
Thustheclinical evidence for the value of FSUmin is conflicting, and of limited value
for this analysis, since it is influenced by unknown dataset characteristics. The value of
0.47, resulting in the appropriate complication rate mentioned above, will be used.
6.3.4 Inter-patient variation in radiosensitivity
Whenconstant parameter values are used all patients are assumedto beidentical, except
for the dose distribution (which depends on tumourposition and size). To represent the
inter-patient variation in radiosensitivity, a was sampled from a log-normaldistribution,
since a is bounded by zero, with a standard deviation of 7, = 25%. This would be
expected to flatten the dose-response curve, if the complication rate is plotted against
different prescription doses (simulating a dose escalation study). However, this variation
in @ hadlittle or no impact on the complication probability when a set of lung-type dose
distributions was considered, since the range of complication probabilities associated
with the different dose distributions was large enough to overshadow theeffect of the
variation in radiosensitivity; see discussion in section 5.8.
Therefore, the value of gg cannot be deduced from such a curve in a dose escalation
study. Instead clues can be obtained from the expected range in the local dose response
curve of the FSUs (figure 6.3), and from the variation in radiosensitivity between
different mouse strains, which suggests og = 18% [52]. To guarantee adequate FSU
 
?Only an absolute volume was given, but a relative value was calculated assuming normal lung
volumes.
3When deriving FSUmin from the volume which must be spared, it is assumed that the volume
outside the ‘critical’ CFV receives doses below the threshold, and thus FSUmin = (volumespared -
(1-CFV))/CFV.
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survival at doses tolerated for total lung irradiation (see discussion above), a similar
value of 7 = 15% will be used for lung simulations.
6.3.5 Inter-patient variation in health status
In a clinical setting patients will differ, not only in stem cell radiosensitivity, but also in
health status and lung volume, and therefore in functional reserve. This is represented
in the model by an inter-patient variation in pre-treatment (uniform) FSU density(i.e.
the numberof pre-treatment FSUs per voxel, NéSU). This is suitable since previous
lung damage (caused e.g. by smoking) causes damage throughout the lungtissue.
Perhaps more importantly, it has been shown that the clinical manifestation of
radiation pneumonitis is correlated to the strength of the inflammatory response to
irradiation, and that this is different for different individuals [146]. It would be more
intuitive to represent this by a varying FSUpin, but in practice the effects of varying
NESU and FSUmin are equivalent for a uniform FSU distribution, since both affect the
ultimate comparison of the number of surviving FSUsin the ‘critical’ CFV to FSUmin,
which decides whether a complication occurs.
One source of information concerning the variability in health status among lung
cancer patients is the level of correlation observed between mean lung dose (MLD) and
complication probability. This variability acts as a confounding factor in dose-volume
analyses, so that increasing variability in health status should result in weaker correlation
between MLD and outcome; see chapter7.
This relationship was explored by simulating 1000 lung-type radiotherapy treatments
with the 3D model. As expected the outcome correlated strongly with MLD, but
with increasing variation in pre-treatment FSUs per voxel, NeSU this correlation was
weakened. In these simulations NFSU was randomly sampled from a log-lognormal
distribution since it is bounded by zero and one.
Figure 6.5 illustrates the influence of this increase in the population standard
deviation of NESU opsy, representing the health status variability. For each orsu
the same treatments (with the same set of 1000 dose distributions) were simulated 10
times, each time sampling new values of NéSU. In all simulations gg was kept at 15%.
Figure 6.5 shows the mean and standard deviation of the strength of correlation between
MLDand outcomefor these simulations, in terms of the area under the ROC curve. A
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Figure 6.5: Simulations with different population standard deviations in the pre-
treatment number of FSUs/voxel. The data points show the mean area under the ROC
curve (AUC) for MLD,and standard deviations, for 10 simulations. The correlation
between MLD and outcomedecreases when the variation in pre-treatment ‘FSU density’
(argv) is increased. This correspondsto an increased level of confounding factors which
weakens the link between the dose distribution and outcome. The choice of orgy must
give a realistic value of AUC.
few clinical studies have reported the AUC for MLDas a predictor of radiation-induced
lung toxicity. However, orgy cannot be determined from these reports since AUC
ranges from 0.47 to 0.94 [147, 148, 149, 150, 151]. As shown in chapter7, this variation
might be dueto different levels of confounding factors and complication rates, as well
as different variability in MLD, in the different datasets.
Instead, a different approach was tried, where the p-value of simple univariate
correlation analyses between MLD and pulmonary toxicity was reproduced. Theresults
from three dose-volumestudies on non-smallcell lung cancer patients were imitated in
terms of sample size and numberof complications [89, 152, 153]. By simulating these
studies using different values of orgy, the p-value for a univariate logistic regression
analysis of MLD and outcome could be compared to the results of these studies, and a
suitable value of orsy could beselected. Lung-type dose distributions were used, and
parameter values as reported above. Each study was simulated fifty times, selecting the
appropriate numberof dose distributions from the set used in the simulations in the
ROCanalysis above, and the value of N&SU was sampled for each patient as described
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above. Table 6.1 shows the range of p-values which resulted for each of the scenarios,
for one value of orgy.
Table 6.1: The median and range (1° and 3"4 quartiles) of the p-value for the correlation
between MLD and outcomefor 50 simulations, imitating the results of three clinical
studies whilst assuming orgy = 25%.
 Imitated study median p 1% quartile 3"? quartile
Yorke et al. [153], p = 0.04 0.18 0.027 0.37
Graham etal. [89], p = 0.10° 0.026 0.0019 0.12
Hernandoetal. [152], p= 0.005° 0.0026 28x10 0021
®9/49 (18%) > grade 3 lungtoxicity
522/99 (22%) > grade 2 radiation pneumonitis
©39/201 (19%) > grade 1 pulmonarytoxicity
As expected, the choice of orgy influenced the p-value of the univariate correlation
analysis, and as is evident in table 6.1 the range of p-values depended on thesize of the
dataset. The chosen value of orgy = 25% gave representative strengths of correlation
for the three scenarios; p-values both higher and lower than those observed in the three
studies were generated by the simulations. This value of orgy also led to a plausible value
for the strength of the correlation between MLD and outcome of AUC = 0.66in figure 6.5.
Asseen in table 6.1, the variation in observed strength of correlation depended on
the numberof patients in the simulation (increasing towards the bottom of the table).
Interestingly, simulations of the smallest study by Yorke et al., which resulted in a low
p-value, suggest that in most cases such a small study would not show significant
correlation between MLD and outcome. Thus, large patient groups are required in order
to be sure to detect correlations between dose-volume parameters and outcome, when
there is influence from confounding factors.
6.4 Rectum
Prostate cancer is the most common type of cancer amongst men [131]. During
radiotherapy the whole gland is generally considered a target, which exposes the rectum
to high doses, since the anterior wall is adjacent to the prostate. The position of the
rectum makes it less mobile than the rest of the intestine, which results in the same
section being consistently irradiated throughout the treatment, making the rectal wall
susceptible to injury [154].
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6.4.1 Radiation-induced rectal toxicity
Acute complications of the bowel occur during or soon after treatment and consist
of diarrhoea and pain, mucous discharge, tenesmus and bleeding. These symptoms
generally subside within 2-3 months [155]. However, some patients experience chronic
rectal complications which often appear monthsto years after therapy [156, 157]. Rectal
bleeding, faecal urgency, incontinence and more frequent bowel habits are common
amongst these patients [158]. It is believed that the target cell for acute effects is the
stem cell of the epithelium, whilst chronic effects are predominantly dependent on the
integrity of the endothelial cells in the microvasculature [128, 24, 13, 129].
One of the most common late complications after irradiation of the rectum is
bleeding [159, 160]. Whilst this is generally transient and well tolerated by patients [159,
160}, severe bleeding is often persistent and requires difficult interventions [155]. The
main cause of rectal bleeding is telangiectasia [161, 158, 159, 160], which appears as
dilated and abnormally structured mucosal microvasculature [162, 163]. Although the
pathogenesis of telangiectasia is not fully understood, it is generally attributed to
damage of the microvascular endothelium [162, 163, 24, 164, 165, 13, 19].
However, telangiectasia does not explain all cases of bleeding, and not all patients
with telangiectasia experience rectal bleeding {161, 160]. Another causeof rectal bleeding
is ulcers, but like telangiectasia the ulcers are ultimately also due to radiation-induced
endothelial cell degeneration since this leads to loss of microvasculature, and the ischemia
which ensues canset off this ulcerative process [24, 165]. Thus, rectal bleedingis related
to damaged endothelial cells, whether directly through telangiectasia or indirectly
through mucosalulcers, and it will be assumed that the target cell for rectal bleeding is
the endothelial cell in the mucosal microvasculature.
6.4.2 Geometrical representation
In the 3D model the rectum was represented by a single voxel tube with a square
cross-section; see figure 6.6. The side of the square was 2.8 cm, calculated from the
cross-sectional area given by the mean rectal diameter of 3.2 cm [166], and the length
of the rectum was equal to the 50 voxel side length of the array, corresponding to
12 cm. Further, the rectal wall thickness was assumed to be 2.4 mm,since this was the
width of the voxel (12 cm/50 voxels), and it is close to the average thickness in normal
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anatomy [167]. As shown in section 6.4.3, there are 64 FSUs/mm?rectal wall, which
means 370 FSUs/voxel.
 
  
 
 
 
 
Figure 6.6: Geometrical representation of the rectum in the model. The blue volume
represents the rectal wall, and the purple volume is the GTV, which does not overlap
with the organ at risk. The surrounding white volumerepresents all other tissues and
organs in the pelvis.
6.4.3 Modelling local tissue damage
The FSU of rectal bleeding
Asfor the lung above, information about the identity of the FSU of the rectal microvas-
culature was searched for in the literature, in order to determine values for @ and Nee.
In the rectal wall the capillaries are organised in clusters around mucosal glands which
have a diameter in the order of 0.15 mm [168]. Since endothelial cells can migrate over
distances of 0.3-2 mm [169], and all capillaries in a cluster seem to drain into a single
venule {168], and thus are in physical connection, it is reasonable to assume that a single
proliferating cell can regenerate all endothelial cells in such a capillary cluster. Thus, the
FSU of the rectal microvasculature is assumed to be the capillary cluster, with a density
of 64 FSUs/mm? smoothrectal wall, as counted from figure 2a in reference [168].
Figure 6.7 shows a schematic illustration of a segment of the rectal microvasculature.
The endothelial cell is 25-50 wm long and 10-15 ym wide, and the capillaries are 7-
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10 ym in diameter [170]. Kessel [170] also reported that the maximum distance to a
capillary from any cell in the body is 50 wm, which is in agreement with the average
inter-capillary distance of 107.2 wm in the large intestine found by Fait et al. [168].
Given these dimensions, around 441 capillary segments of length 2.4 mm fit in one voxel,
each with a wall area of 64,000 zm?. From thesize of the endothelial cell, the number
of cells per capillary segment was estimated to be 174, which amounts to 208 cells per
FSU. According to Rubin [13] one in 10-20 of the endothelial cells is proliferating, which
would suggest an Ng- of 21-42.
Capillary diameter = 7-10 um
> X= 110 um
EC width = 10-15 pm
EC length = 25-50 pm
Figure 6.7: Schematic illustration of the proportions of capillary size, endothelial cell
(EC) size and inter-capillary distance (X).
 
Unlike the epithelial cells in e.g. lung and intestine, endothelial cells retain the
capacity to proliferate even in their differentiated form [171, 172]. Following cell loss,
remaining endothelial cells stretch and migrate to immediately repair the endothelium,
and eventually the cell density is recovered through proliferation of a small portion of
the population [173, 174, 171].
The endothelial cells are also different in that they undergo apoptosis rather than
mitotic cell death, if damaged by radiation. The endothelial population maintains a
balance between proliferating and quiescent cells, and cells escape this cycle through
apoptosis, if damaged, or through senescence (ageing), at the end of their life span or
triggered prematurely by damage to the DNA. Theproliferating cells are distributed
randomly throughout the endothelium [171], and go through a maximum of 20-50
divisions [175]. Endothelial cell loss, caused by e.g. radiation, is compensated for by
quiescent cells entering the mitotic cycle [164]. There is also evidence that stem cells
from the systemic circulation can be a source of new endothelial cells [172].
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Dose response of the FSU
A threshold dose for FSU inactivation of 35 Gy is assumed, based on a correlation analysis
on a large dataset with varying treatment techniques and prescription doses [113], and
a study estimating the local dose response to outcome with a cluster model [68]. As
mentioned in section 6.3.2, the threshold dose gives the iso-effect relationship between
@ and Nsg-; see figure 6.8. The figure suggests that for the expected values of Nec
between 21-42, @ is in the range of 0.033-0.047 Gy!. This is in line with the low
value of a = 0.01 Gyreported for the rat rectum [176], and 0.04-0.11 Gy?! for
telangiectasia [177].
 
 
0 0.05 0.1 0.15 0.2 0.25 0.3x aa(Gy~})
 
 
Figure 6.8: Values of & and Ng, resulting in 99% FSU survival at 35 Gy. The expected
range of a, and the combination of @ and Ng, associated with the capillary cluster as
the FSU of rectal bleeding, are indicated.
Low values of N;- result in very shallow dose-response curves for the FSU. The
slightly higher value of Nsc = 50 in combination with @ = 0.05 Gyis shown to give an
appropriate slope in figure 6.9, with a dose threshold of FSU inactivation around 35 Gy,
major FSU inactivation at 60 Gy (60% FSU survival), and a saturation of effect above
clinically relevant doses.
These results are consistent with doses < 25 Gy (EQD2) considered low, > 60 Gy
high, and doses in between intermediate, by van Lin etal. [161] and Wachter etal. [178].
These reports might contain the most relevant dose-response data since they link
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Figure 6.9: Median of FSU survival with 5 and 95% quantiles for different local doses;
Nese = 50, & = 0.05, og = 15%. The position and the slope of the curve are a result of
these parameter values, which follow from identifying the capillary cluster as the FSU
for late rectal bleeding. Intermediate doses cause a moderate level of FSU inactivation,
and high doses severe FSU inactivation.
local dose to grade of telangiectasia. They show that local doses of at least ~ 30 Gy
occasionally result in low grade telangiectasia, ~ 50 Gy commonlyin low or high grade
telangiectasia, and ~ 60 Gy frequently in persistent high grade telangiectasia. These
results compare well with figure 6.9 where the curveis the steepest at 50-80 Gy, so that
these doses result in very different levels of FSU kill for patients with different intrinsic
radiosensitivity.
The shallow slope of the curve in figure 6.9 also provides an explanation for the
difficulty of identifying a single important dose constraint for late rectal bleeding;
a range ofclinically relevant doses cause an increasing level of local tissue damage,
and the importance of these doses depend on the volumes treated. However, this
interpretation assumesa significant volume effect for rectal bleeding. This will be
discussed in section 6.4.4.
Note that here Ns. represents the numberof proliferating endothelial cells in an
FSU rather than a stem cell population as such. Since the putative endothelial stem
cells circulate throughout the body it is unlikely that this populationis influenced by
local irradiation, which justifies not taking these into account for Ns-. This source of
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new endothelial cells would rather be expected to reduce the effective radiosensitivity
of the endothelium, which might explain the low values of @ found in this analysis.
In this case a lower tolerance dose or a steeper dose response would be expected for
endothelial cells in vitro compared to in vivo, since in vitro there would be no access to
stem cells from the systemic circulation; and indeed endothelial cells appear to be more
radiosensitive in vitro compared to in vivo [179].
The a/f ratio
Asa late effect, rectal bleeding would be expected to have a low a/( ratio. However,
there are several reports of values between 4.4 and 6.65 Gy for late rectal injury in
general [180, 181, 176, 158], and for endothelial cell kill in particular [182]. The former
could be attributed to its dependence on the endothelial integrity, or if the a/( for
endothelial cells is low after all [177], to a contribution from a consequential acute effect
in the rectal epithelium [181, 158]. Whatever the mechanisms though, for a/G ~ 6 Gy
the dose threshold for significant endothelial cell loss between 14 and 15 Gy in a single
fraction [38] is consistent with the doses of clinical importance for rectal bleeding
described above. Therefore a/ = 6 Gy has been usedin this study.
6.4.4 Modelling loss of global organ function
The volume effect of the rectum, with regard to late bleeding, is controversial [183];
on one hand thereis a relatively strong consensus of the rectum behavinglike a serial
organ, and on the other hand many recommendeddose constraints are for intermediate
doses applied to 35-40% of the rectum (average volumefrom table 1 in reference [183]).
Therisk of rectal bleeding seems to depend mostly on the high-dose region, but large
volumes of intermediate doses also add to the risk [183]. This gives support for the
shallow dose-response of the FSU (figure 6.9), and suggests a rather large CFV for late
rectal bleeding.
In a case-control study Tucker et al. [68] compared thesize of clusters of damaged
area elements in the rectal wall for pairs of patients with similar DVHs but different
outcome. Nofixed cluster size threshold was identified and the authors suggest that
the probability of rectal bleeding increases over a range of cluster sizes. However,it
was shown that there were both cases and controls for clusters of 42-72 cm?, which
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corresponds to roughly 30-55% of the rectal wall. Also, Buettner et al. [113] found that
rectal bleeding was associated with at least 37.4% of the rectal wall receiving > 48 Gy
(in EQD2), and at least 59.1% of the rectal circumference receiving > 59 Gy. Based on
these data the CFV is estimated to be 45%.
Simulations with the parameter values derived so far resulted in plausible complica-
tion rates, for clinically relevant dose distributions, if FSUmin = 0.6 was chosen. Since
clearly not all FSUs are damaged at clinical doses [178], this relatively low FSUmin
seems reasonable.
6.4.5 Inter-patient variation in health status
The response of the rectum of different individuals varies greatly, even when irradiated
under the same conditions [184, 185, p. 185]. The first explanation to consider (apart
from uncertainties in delivered doses, e.g. due to inter- and intra-fraction movements of
the rectum) would be a large inter-patient variation in endothelialcell radiosensitivity.
However, there not only seems to be a patient-specific factor (as opposed to treatment-
specific) in the developmentof rectal bleeding for a given dose level [68], but also for a
given level of local tissue damage in termsoftelangiectasia [161, 178]. This indicates
that the inter-patient difference in overall response of the rectum is not fully explained
by a difference in radiosensitivity of the target cell of the tissue; for a givenlevel of local
tissue damage someindividuals are more prone to develop rectal bleeding than others.
This is not surprising considering that atrophic mucosa, caused by loss of microvas-
culature, can develop ulcers if exposed to a certain level of faecal mechanical stress,
which might be influenced by e.g. the diet [186, 176]. Therefore the tolerated level
of local tissue damage varies from patient to patient. This inter-patient variation in
the propensity to develop rectal bleeding could be modelled by sampling the value
of FSUmin, but like the health status variation for lung this is instead modelled by
sampling the pre-treatment FSU density. A value of orsy = 10% seemsplausible.
6.4.6 Inter-patient variation in radiosensitivity
Above, orsy did not represent a variation in health status as much as a general variation
in global organ response. Similarly, og will be used to model all variations likely to
impact the local tissue response. One of these factors seems to be chance,since the level
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of telangiectasia following radiotherapy is related not only to the local dose. Safwat et
al. [187] explored the stochastic versus deterministic contribution to such inter-patient
variation in tissue response by comparing the grade of telangiectasia in two different
areas of the skin of each patient, after breast radiotherapy. They found that 10-19% of
this variation was due to stochastic factors, and the rest to factors which in principle
could be known.
This indicates that, in the rectum in contrast to the lung, the binomial standard
deviation in FSU survivalis of clinical significance. The magnitude of the binomial
NFSUstandard deviation depends on the numberof pre-treatment FSUs per voxel, No
and the probability of FSU survival, Ppgy (given by equation 6.1). At the average
dose of Safwat’s study, Prsu ~ 0.77 with the values of Nec, &, a/ and NéSU Chosen
above. This gives a standard deviation of 2.9%, which should correspond to 10-19% of
the total inter-patient variation in local tissue response, according to reference [187].
Thus, 7 = 15% will be used, since this corresponds to 84% of the total inter-patient
variability in local tissue response, and the remaining 16% is given by the stochastic
factor as described above.
Safwat et al. supported the hypothesis that the remaining, deterministic, portion of
the variation is due to the intrinsic radiosensitivity. Further support for this hypothesis
was recently given by the ground-breaking study by Valdagni et al. [188] where the
risk of rectal bleeding largely depended on the individual’s gene profile, in addition to
dose-volume parameters for the rectum.
Apart from the variation in intrinsic radiosensitivity and the stochastic factor in
FSU inactivation, og might also be influenced by other patient-specific factors such as
age and comorbidities [187]. As discussed above, these might be related to the function,
andlevel, of endothelial progenitor cells in the circulation.
6.5 Discussion and Conclusions
6.5.1 Results from the simulations
It was found that the local dose-response of the pulmonaryepithelium is relatively steep,
with increasing FSU inactivation over a range of 6-22 Gy. The dose-response of the
microvascular endothelium in the rectal wall, on the other hand, is much shallower and
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with a dose threshold around 35 Gy. These findings, together with considerations of the
histology of these tissues, support the hypotheses that the alveolus, and the capillary
cluster around a mucosal gland, are the FSUs of the lung (radiation pneumonitis) and
rectum (late rectal bleeding) respectively.
In accordance with the consensus in the literature the lung was found to have
a large functional reserve, and it seems that the inflammatory process caused by
radiation-induced tissue damageholds the key to the volume effect; above a threshold
of radiation-induced tissue damage within the CFV, secondary FSU inactivation,likely
due to inflammation, develops throughout the CFV andresults in organ failure.
Therelatively large value of the rectal CFV found in this study is at odds with
the common perception of late rectal bleeding as a serial endpoint. However, there
are contradictory results concerning the dose range most important for causing rectal
bleeding, and the shallow local dose-response curvefor local tissue damageindicates that,
although large volumes of intermediate doses contribute to the complication probability,
high doses are indeed the most important. This could explain the appearance of a
small volume effect in some studies, since even a rather small volumeof intensive FSU
inactivation caused by high doses can result in the number of FSUsin the larger CFV
falling below FSUmin, but for a different set of dose distributions significantly lower
doses to a larger portion of the CFV would have the same effect. In the former case it
would be concluded that the volumeeffect is small and the dose important for bleeding
high, whilst in the latter the volume effect would appear larger and the important dose
lower.
The parameter values proposed in this chapter are based on the best data available,
but as discussed in the next section the radiobiological knowledge base for mechanistic
NTCP modelling is not yet complete. In chapter 7 these parameter values were used
for generating pseudo-clinical normal-tissue data for lung and rectum, and DVH-based
NTCP models werefitted to the resulting datasets. The LKB model parameter values
(tables 7.1 and 7.2) differ from recently published meta-analysis data [130, 157]. Although
this might partly be due to differences in dose distributions included in the studies, the
representation of lung and rectum by the 3D modelclearly has limitations.
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6.5.2 The radiobiological knowledgebase
Apart from finding parameter values for the 3D model which would result in clini-
cally relevant simulations, the aim of this chapter was to highlight areas which need
further research for predictive mechanistic NTCP modelling to be feasible. There is
an extensive literature about the effect of radiation on normaltissues, and in spite of
the difficulties of producing systematic and reproducible data for normal tissues, great
progress has been made; well-foundedclinical experience prevents large numbers of
patients experiencing serious side-effects from radiotherapy. However, before predictive
mechanistic modelling can be developed and used for individualised treatment planning,
more specific quantitative data are necessary [74, 33, 21].
It was found that only weak evidenceis available for the value of normal-tissue
stem cell radiosensitivity parameters, as well as for the identity of the FSU. Also, it
is to be expected that the local dose-response of the tissue is influenced not only by
these parameters, but also by factors such as comorbidities and the supply of stem
cells from the systemic circulation. However, for the purpose of predictive mechanistic
modelling, the first step would be to identify the dose-response curve for local tissue
damage, with small confidence intervals. If this were verified to be consistent underall
relevant conditions, the parametersfitted to this curve, @ and Ngc-, could be considered
operational without muchloss of credibility for the mechanistic model, although future
data from radiobiology studies on normal-tissue stem cells might be able to elucidate
effects also on this level.
This indicates that, above all, more quantitative histopathological studies on relevant
local dose effects are wanted, for great ranges of dose and irradiated volume. It is also
of great importance to determine the link between clinical symptoms(e.g. bleeding)
and histopathologic conditions (e.g. microvascular malformations). This can be done
by a combination of animal models andlargeclinical studies, where follow-up includes
evaluation of the local function/appearance of the tissue in regions which received
different dose levels, as well as symptom-oriented questionnaires. It is important that
such studies are designed to test specific hypotheses of pathogenesis [157].
Data from such studies could also be used to explore how the build-up of tissue
damageoverincreasing volumes,of different shape, influencetherisk of clinical symptoms.
Such volumeeffects could be studied systematically in animal models, and the hypotheses
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these generate should be tested in large clinical studies. The success of these studies
would depend on accurate knowledge of the dose delivered to small volumes of organs at
risk. Therefore current developments in immobilisation, imaging and in vivo dosimetry
are encouraging.
Finally, once more data of this kind are available further modelling studies are
necessary to put the many pieces of this jigsaw puzzle together and interpret the
findings. In this study only one endpoint was considered for each organ, but for some
organs, like the rectum, there are several endpoints influencing the quality of life of
long-term survivors, which should all be studied similarly.
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Chapter 7
The Performance of NTCP
Models in the Presence of
Confounding Factors
7.1 Introduction
NTCP models have long been used in the analysis of clinical data, and there is a
multitude of studies where model parameter values have been fitted to local datasets.
In most of these studies a single DVH-based NTCP modelis used, but there are a few
where a numberof models have beenfitted to the dataset. In these studies it is generally
concluded that the performanceof all modelsis similar [189, 101, 85, 43, 44, 75, 49, 76].
Whetherthis is due to limitations in the datasets or because no model is better than
any of the others is not clear.
One limitation of most datasets, for the purpose of discerning differences between
model fits, is the presence of confounding factors, i.e. non-dosimetric factors influencing
the outcome independently of the dosimetric variables considered by the NT'CP models.
Inevitably all models perform less well when applied to datasets with high levels of
confounding factors, but it is also expected that any differences in performance between
models might be obscured when they cannot be fitted to outcome data relating to
the dose distributions only. The importance of considering non-dosimetric factors for
predicting the risk of a complication has been demonstrated in several studies [148, 100,
190, 191, 192].
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7.1.1 DVH-based modelling
The job of an empirical NTCP model is to “summarise” the information of a dose
distribution into a single metric, as efficiently as possible, in order to predict the risk of
a complication occuring for a given treatment plan. Ideally the model would predict
either 0% or 100% NTCP with a very small confidence interval for all plans, because
then a safe plan could be distinguished with certainty from one which would cause a
complication. However, this is generally not possible since (1) an empirical NTCP model
cannot perfectly summarise the relevant features of a dose distribution, (2) not only the
dose distribution but also patient specific factors (confounding factors) influence the
outcome. Someof these confounding factors might be known andcould in principle be
accounted for by the model, but generally they simply influence the model fit to make
the slope of the function between the summary measure and NTCPshallower(larger
m; see chapter 2).
The parameter characterising the slope of this curve represents the variability in
responsein the population andis closely connected with the performance of the model. If
the curve approachesa step function (m — 0) the chosen dose-effect measure successfully
summarises the data andall relevant patient-specific factors are taken into account. In
this case the model separates responders from non-responders well, which results in a
large area under the ROC curve (AUC) (see chapter 3). Thusit is desirable to find an
NTCP model resulting in a high AUC, i.e. a model whose local dose-effect measure
summarises the dose distributions so well that the (steep) slope of the response function
is due to confounding factors only.
In this chapter DVH-based NTCP models arefitted to pseudo-clinical data generated
by the 3D model, for different levels of confounding factors, in order to compare the
performance of the models. The parameter values derived for lung and rectum in
chapter 6 are used, and to simulate varying levels of confounding factors the values of
Oq and orgy are varied. Thus the performance of the fitted models can be explored as
a function of the strength of these confounding factors, and the ability of the various
models to summarise the dose distributions.
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7.1.2 NTCP modelling beyond the dose distribution
Since the performance of NTCP models, and thus their usefulnessin clinical practice,
is reduced by confounding factors such as inter-patient variations in health status and
radiosensitivity, it would be desirable to find methods for removing the influence of
these factors. This is of increasing importance the better the models can account for the
influence of the dose distribution on the complication probability. In particular, where
treatments are planned based on iso-NTCP the dosedistribution might not predict the
outcome [42], since then all plans are supposedly close to the limit where they would
cause a complication, and the patients actually responding with a complication are
likely to be amongst the most radiosensitive ones or because of other patient-specific
factors be especially susceptible.
In order to move beyond the dose distribution, it is important to identify any
non-dosimetric factors influencing the risk of toxicity. However, these factors cannot be
accounted for unless methods are developed to classify individuals into risk groups. For
some factors, such as smoking status or comorbidities, this should be feasible, whilst for
others, such as intrinsic radiosensitivity, there is currently no practical method to find
out where on the scale any given patient belongs. As will be shownin this chapter, the
potential gain from including relevant non-dosimetric factors into the models motivates
research in this area.
If individuals could be stratified according to somerisk factor, DVH-based NT'CP
models could be fitted to subgroups of the larger dataset to obtain parameter values
tailored to each patient group. When applied in the clinic the appropriate parameter
set would be chosen based on which risk group the patient belonged to. If several risk
factors were known the subgroups would be furtherstratified for each factor. This
method would result in steeper response curves for the summary measures, and thus
in principle an increase in the AUC measuring the model performance, but it makes
inefficient use of the statistics of the dataset, since the models are fitted to small subsets
without any input from the other patient groups.
A better method is to account for the non-dosimetric factors in the modelitself.
This has been doneeither by including both dosimetric and non-dosimetric variables in a
logistic regression model [100, 190], or by the use of a ‘dose modifying factor’ [193, 191].
In this study, both the logistic regression (logit) function and the cumulative normal
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(probit) function will be used with three independent variables influencing the outcome:
the summary measure, the radiosensitivity (a) and the health status (N#’SY). Each of
these three factors is known to be important for the outcome in the present datasets,
and thus overfitting should not be an issue.
7.2 Methods
7.2.1 Simulations
Pseudo-clinical data were generated with the 3D model of normal-tissue response to
radiotherapy, described in chapter 4. In order to represent lung and rectum compli-
cation data, the parameter values selected in chapter 6 were used. Each patient was
characterised by a unique dose distribution and individually sampled values of a and
NeSU representing their personal radiosensitivity and health status. All datasets had
different combinations of og and orsy but were based on the same set of 1000 dose
distributions (separate sets for lung and rectum).
The lung dose distributions were generated as described in sections 4.3.4 and 5.1.
In the case of the rectum, beamswere directed at the target (prostate) in a four-field
box technique, such that the anterior and posterior beams always covered the rectum
whilst the portion covered by thefields from theleft and right varied from patient to
patient. The DVH of the rectum was generated based on the voxels of the rectal wall
(excluding therectal filling). The variation in beam widths and doses was adjusted to
make the DVHs resemble rectal DVHsfrom prostate treatments at Clattrebridge Centre
for Oncology, using the methodsdescribed in section 5.1.
Both for lung and rectum five datasets were generated: one without confounding
factors (0 = orsu = 0), one with the values of og and orgy derived in chapter 6, and
three with either og or orsy set to zero. Out of these one was generated with oq or
orsu set to the value derived for the other in order to comparetherelative effect of
these confounding factors on the model performance.
7.2.2 Fitting NTCP models to simulated data
Seven DVH-based NTCP models werefitted to each dataset: the LKB model, the mean
dose model, the maximum dose model (¢ = Dmaz), the relative seriality model, the
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4-parametercritical volume model, the 3-parameter critical volume model and the Vpip,
model. These models were described in section 2.1. Generally the models werefitted
using the maximum likelihood method but when the solutions were unstable, simulated
annealing and/or visual inspection of the parameter likelihood space were used to find
the bestfit.
The performance of the modelfits was evaluated in terms of the area under the ROC
curve (AUC) when applying the fitted modelto the fitting dataset. This assesses the
ability of the model to link the outcome to the dose distributions. However, if this were
the only criterion for a good model, the choice would be one with many parameters,
which would rely on random features in the dataset and thus be much less successful for
a different dataset. Therefore, two different model fits were applied to a ‘test dataset’:
the first fitted to a ‘fitting dataset’, and the other to the test dataset itself. Any case
of overfitting would then be detected by finding the AUCfor the modelfitted to the
fitting dataset to be significantly lower than that for the modelfitted to the test dataset
itself. The fitting and test datasets were different but equivalently generated, and whilst
the test dataset consisted of 500 patients, the size of the fitting dataset was gradually
reduced from 500 until the difference between the AUC for the two models, applied to
the test dataset, was significant.
7.2.3 Models including patient-specific factors
Since the argumentof the logistic regression modelis the sum of any numberofcovariates,
which can be numerical or categorical, non-dosimetric variables can easily be included.
The covariates can be summary measures as well as biological or clinical parameters.
A logistic regression-based model [45, 194] calculates the logarithm of the odds of a
complication occuring as a sum of the contribution from the n covariates X;:
( NTCPIn NTCF) = Bo + By X41 + BoX2 +..+ BiXG (7.1)
Here {po is called the intercept and the magnitude of the parameter @; depends on the
strength of the influence of X; on the odds. X would typically be the summary measure
(¢), and X2...X, any patient-specific variables included in the model. The NTCP is
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then given by
1
oe = 1 + e—(80+81X1+62X2t...+BnXn) * (7.2) 
The parameters of this model(0, (1, ..., 8n, and any parameters of summary measures)
can be fitted to a dataset with the maximum likelihood method (equation 3.2).
Also the cumulative normal function can be used with a set of covariates [194]. With
the dose modifying approach mentioned above, non-dosimetric factors are included
in the LKB model by adjusting the effective TDs9 for different subgroups. Thus the
EUD responsecurveis shifted along the EUD axis, whilst using fixed values for the
other parameters. However, there is also a method of combining the cumulative normal
function with non-dosimetric variables which treats all influencing factors as independent
covariates, similarly to the logistic regression model. Here ¢ in equation 2.2 is modified
rather than T'Ds0:
t = Bot BiX1 + BoXet+... + BrXn- (7.3)
Alternatively this can be expressed in terms of the usual probit model parameters ¢59
 
and m:
t= P= 90 4 BX 4. + BaXn, (7.4)m + O50
where §, ..., Gn are the model parameters for the non-dosimetric factors X9,..., Xn.
These two expressionsfor ¢ are related with the following parameter transformation:
$50 = —Bo/P1
m = —1/Bo
7.3 Results
7.3.1 The influence of confounding factors
In the overfitting test the difference in AUC for the models fitted to the fitting dataset
and the test dataset respectively was statistically significant in only one case: the LKB
modelfitted to the first lung dataset. However, this difference in AUC was borderline
and only appeared in the third AUC decimal. Thus the AUC for the fitted models
applied to the fitting dataset itself could be used as a measure of model performance.
Figures 7.1 and 7.2 show the performance of the DVH-based NTCP models when
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Figure 7.1: The performance (AUC) of seven DVH-based modelsfitted to pseudo-clinical
lung datasets which were simulated with different levels of confounding factors, in terms
of the variation in radiosensitivity 7, and health status orsy.
fitted to the lung and rectum datasets respectively, with increasing levels of confounding
factors. Since the models are based only on the DVHs they cannot account for indi-
vidual values of radiosensitivity or health status, which explains the decreasing model
performance with increasing confounding factors.
The AUC was foundto be influenced by the NTCP values (and thus the complication
rate) in the dataset which the model fits were applied to; it was more difficult for the
models to correctly classify DVHs with NTCP ~ 50% than DVHs with low or high
NTCP, and thus performed worse on a dataset with many DVHs with NTCP ~ 50%.
This effect might influence the results in figures 7.1 and 7.2 since the datasets have
increasing complication rate with increasing levels of confounding factors. However,
when similar datasets were generated with parameter values adjusted to produce similar
complication rates, the results still showed a decrease in AUC with increasing levels of
confounding factors.
All DVH-based models fitted to the datasets, except the maximum dose model,
performed similarly well, and the influence of the confounding factors on the model
performance was more important than the choice of model. The superiority of the mean
dose model compared to the maximum dose model, for both lung and rectum data,is
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Figure 7.2: The performance (AUC) of seven DVH-based models fitted to pseudo-clinical
rectum datasets which were simulated with different levels of confounding factors, in
termsof the variation in radiosensitivity og and health status orgy.
consistent with the high values of the LKB volume parameter n, and the low values
of the relative seriality parameter s, in tables 7.1 and 7.2 (at the end of the chapter)
which showall parameter values for the modelfits shown in figures 7.1 and 7.2.
In the first column of tables 7.1 and 7.2 the cumulative normal function parameter,
¢50, represents TDso for the LKB model, the mean dose resulting in 50% complication
rate for the mean dose model, the maximum dose resulting in 50% complication rate for
the maximum dose model, and rdVs9 for the 4-parametercritical volume, 3-parameter
critical volume and Vp;;, models. In general, ¢59 is the value of the model-specific
summary measure of the DVH, at NT'CP = 50%. For therelative seriality model, which
is not based on the cumulative normal function, Ds9 is listed in the first column, y in
the second column and s in the third column. For the other models the cumulative
normal function ‘slope’ parameter, m, is listed in the second column. For the 3- and
4-parameter models, model-specific parameters relating to the DVH reduction into a
summary measureare given in columns 3 and 4.
As expected the value of the slope parameter reflected the amount of inter-patient
variation in the datasets; in both tables m increased and y decreased with increasing
variation. The values of ¢59 and Dso were generally consistent amongst the datasets,
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except the unrealistically high $59 for the maximum dose modelin table 7.1 which
confirms that this is an unsuitable model for lung datasets.
For the lung datasets (table 7.1), 59 of the LKB model was lower than ¢509 for the
mean dose model, and n was consistently greater than one. This means that the LKB
model found lower doses to be important (or the volume receiving lower doses), which
is in line with the suggestion in the next section that critical volume type models might
be moresuitable for lung datasets. The performanceof the relative seriality model was
very similar to the mean dose model, and table 7.1 shows that ¢59/Ds50 was very similar
for these models.
For the rectum datasets (table 7.2), n had intermediate values. Thus the LKB
modelfits correctly identified a smaller volumeeffect for the simulated rectum than for
lung. In contrast the relative serialiy modelfits resulted in surprisingly low valuesofs,
indicating a large volumeeffect, and Ds9 was lower than ¢59 of the LKB model, but
higher than ¢59 of the mean dose model. Interestingly, 659 and m of the critical volume
type models were similar to the corresponding parameters fitted to the lung datasets,
though Dso was higher.
Whilst Dso for lung had a value causing very high FSU inactivation(cf. figure 6.3),
Dso for rectum corresponded to local doses causing very low levels of FSU inactivation
(cf. figure 6.9), except for the Vp:, modelfitted to the last rectum dataset. In a few
cases the probaility distribution of the parameters showed two peaks when fitted to
rectum datasets, with a low Dso and high ¢59 or a high Dso and a low ¢59 respectively.
However, in most cases the probability of Ds9 ~ 35 was higher than Ds9 ~ 63, as
shown by the maximum likelihood estimates in table 7.2. This shows that although
the parameters of the critical volume type models have a biological interpretation, as
empirical models they cannot be assumedto represent the true dose volumerelationship.
7.3.2 The relative model performance
Although the performance of most models wassimilar, for the lung datasets the three
critical volume type models (the Vp, and the 3- and 4-parametercritical volume models)
were consistently superior (p < 0.05, except Vptn compared to LKB for the second
dataset with p = 0.08). For the simulated rectum datasets, on the other hand, both
types of models performed equally well. The reason for this could be that the outcome
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for the lung simulations is predominantly linked to the damaged volume, due to the
large CFV,and thus better predicted by the critical volume models which reduce the
DVH to a volume; whilst the intermediate CFV of the rectum could makethespatial
distribution of damage especially important, which is lost in all DVH reduction schemes
(see related discussion in section 5.7).
The pattern of the difference in AUC between thecritical volume type models and
the other three well-performing models (the LKB, mean dose andrelative seriality
models) was studied in more detail, as a function of orgy. This difference was expected
to decrease as AUC approached 0.50, as the confounding factors grew stronger. For
values of orgy between 0 and 50% (aq = 0), models were fitted to five simulated
200-patient datasets, in order to provide information about the variation in model
performance for different datasets, and thus the uncertainty in the difference between
the model groups.
Figure 7.3 (a) shows the actual mean AUC at each orgy, for all models in the
comparison, and figure 7.3 (b) shows the difference in mean AUC betweenthecritical
volume type models and the other three well-performing models, together with the
standard error of the difference, based onthe five datasets. It was found that rather
than continuously decreasing, the difference in model performance wasrelatively large
(0.07) below a threshold of the level of confounding factors, and smaller (0.03) above the
threshold. Since the detection of a difference between types of models depends on there
being enoughstatistical power in the dataset to select the ideal summary measure (which
is made difficult by cross-correlation between dose-volume parameters), these results
indicate that this statistical power is lost rather suddenly, compared to the continually
decreasing correlation between model prediction and outcome with increasing orsv.
Thus, although models have performed equally well for real clinical datasets so far,
differences might be discovered if confounding factors are taken into account.
7.3.3 Model performanceafter stratifying for patient-specific factors
Clinical outcome data inevitably include significant levels of confounding factors. How-
ever, if the radiosensitivity and health status (and any other important non-dosimetric
factors) were knownfor all patients, and could be quantified, the dataset could be
stratified for such patient-specific factors, and the models fitted separately to each
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Figure 7.3: (a) Mean AUCfor six well-performing models for 5 equivalently generated
datasets of 200 patients each, at different levels of orgy. (b) The difference in average
model performance (mean AUC), for simulated lung data, between two groups of
DVH-based NTCP models: three critical volume type models (the Vp:;, and the 3- and
4-parameter critical volume models) and the other three models (the LKB, mean dose
and relative seriality models).
subset. This would lead to a lower level of confounding factors since in each sub-
set all patients would have similar radiosensitivity and health status. DVH-based
models would then be expected to perform better for each subset compared to the
total dataset. However, the parameter values would be different for each subset, and
the right parameter set would have to be chosen when applying the model to a new
patient.
This hypothesis was tested by stratifying dataset 5, which included inter-patient
variations in both radiosensitivity and health status, into four groups of similar a, and
these groups into four further subgroups of similar N¢’SU The models were then fitted
to each of the 16 subgroups and their performance evaluated. The results for two of the
models, fitted to the simulated lung dataset 5, are presented in table 7.3 (LKB model)
and table 7.4 (3-parametercritical volume model). Similarly, tables 7.5 and 7.6 show
the AUCs for these models fitted to the simulated rectum dataset 5.
As expected, a great improvment was seen in some of the subgroups, compared to
when the models were fitted to the total dataset. For example, when the LKB model
wasfitted to the total dataset of table 7.3 (dataset 5 in figure 7.1) the AUC was 0.65,
whilst for the corresponding dataset without confoundingfactors (dataset 1 in figure 7.1)
it was 0.93. Most of the values in table 7.3 are within this range, and someclose to
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the upper limit. A certain variability in the patient-specific factors still exists within
the subsets, since each variable was divided into only four bins. This is reflected by the
values of the AUC generally being lower than that for the dataset without confounding
factors.
As mentioned in section 7.1.2, a great disadvantage of splitting the dataset into
subsets before fitting the models is the loss of statistical power. Many of the subgroups
didn’t have enough responders to give reliable model parameters, and where no or
all patients suffered the complication the models could not befitted at all. Actually
including the patient-specific factors in the models is much moreefficient since, instead
of fitting three parameters to e.g. sixteen different subsets (48 paramter values in total),
five parameters (three dosimetric and two non-dosimetric) can befitted to the total
dataset, and all information from the data is considered when fitting each parameter.
This method was explored below.
7.3.4 Including non-dosimetric variables
So far only the DVHs were considered by the models fitted to the simulated data.
For most models this was done by reducing the DVH to a summary measure and
?linking it to NTCP via the probit function. In order to also account for the patients
N&S" were now introduced as covariatesradiosensitivity and health status, a and
alongside the model-specific ¢ (see section 7.2.3). This could not be donefor the relative
seriality model, which has a different structure.
Asin the previoussection, dataset 5 for both the simulated lung and rectum data were
used, which included clinically relevant levels of the confounding factors. The different
models were adapted to includepatient-specific factors using both the logit function and
the probit function, as described in section 7.2.3. Tables 7.7 and 7.8 show the maximum
likelihood fitted parameter values. (Go is the intercept, and 61, G2 and (3 the coefficients
associated with ¢, the radiosensitivity and the health status respectively. The other
parameters are the modelspecific parameters required to calculate ¢. In orderto facilitate
optmisation the health status was represented by Ne-/10,000, giving values more
similar to the radiosensitivity parameter a. The positive values of (; and {2 indicate
that higher values of ¢ and a increase the risk of complications, whilst the negative
value of 3 indicates an increase in the risk of complications for decreasing Nemek
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Figures 7.4 (a) and (b) show the performanceof these models and, for comparison, the
performanceof the corresponding standard models for the datasets without confounding
factors (first datapoints in figures 7.1 and 7.2).
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Figure 7.4: Performanceof the logit and probit models including patient-specific factors
for (a) lung dataset 5 and (b) rectum dataset 5, compared to the performance of
the models for the dataset without confounding factors. The models, which included
different model-based summary measures, were the LKB model (e), the mean dose
model (+), the maximum dose model (A), the 4-parameter critical volume model (0),
the 3-parameter critical volume model (x) and the Vp; model (LD).
As expected the performance improved greatly compared to when only the DVH
was considered for the same datasets (dataset 5 in figures 7.1 and 7.2), reaching levels
similar to the performance for datasets without confounding factors. Interestingly,
the poorest models performed better on dataset 5 when patient-specific factors were
considered, than for dataset1 which did not include confounding factors. This does not
indicate that the maximum dose model was a very good summary measure for these
datasets, but rather that including more predictors madeit possible for the model to
classify more patients correctly, since now not only the dose distribution influenced the
outcome.
The performance of the models based on the logit function and the probit function
were essentially identical.
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7.4 Discussion
7.4.1 The AUC as a measure of model performance
In this chapter, the performance of the DVH-based models has been compared in terms
of the AUC for the fitting dataset. The AUC is the probability of a responder having a
higher NTCP than a non-responder whenone of each kind is randomly picked from the
dataset, and thus measures how well the model rank-orders the DVHs. As mentioned
in section 7.3.1, the value of the AUC depends on the magnitude of the NTCPsin the
dataset, since there are moreerrors in the rank-ordering of a dataset where many DVHs
have NTCP ~ 50%, than where most plans have an NTCPof 0 or 100%.
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Figure 7.5: NTCP estimates with 95% confidence intervals (CI) for six patients from
(a) lung datasets 1 and (b) lung dataset 5. Each patient has the same dose distribution
in both figures, but whilst there are no confounding factors in the dataset in (a), values
for the radiosensitivity and health status were randomly sampled when simulating
the dataset in (b). The outcomeis given on the abscissa as complication (x) or no
complication (o). The figures show the NTCP estimates by the LKB model(0), the
mean dose model (<j), the relative seriality model (+), the 4-parameter critical volume
model (A), the 3-parametercritical volume model (x) and the Vp;, model (0D).
This is illustrated by figures 7.5 (a) and (b) which present the predicted NTCP
for a selection of patients in two datasets, the first without confounding factors (lung
dataset 1), and the second with clinically plausible levels of confounding factors (lung
dataset 5). Here the high AUC of the models whenfitted to the first dataset is reflected
by the few intermediate NTCP values in (a), compared to (b), for which dataset the
models had a much lower AUC.
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Similarly, a model which correctly assigns DVHs predominantly very low or very
high NTCPs, reaches a higher AUC than a model with many intermediate NTCP
values for the same dataset. This could be seen, for example in lung dataset 1, where
more patients had intermediate NTCP estimates with the LKB model than with the
3-parametercritical volume model, which had a higher AUC;see figures 7.6 (a) and (b).
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Figure 7.6: Histograms of predicted NTCPsfor lung dataset 1 by (a) the LKB model
and (b) the 3-parametercritical volume model. The lower AUC for the LKB modelis
reflected by more patients having intermediate NTCP values.
It can be concluded that, since a model which predominantly assigns very low or
very high NTCP valuesalso labels plans as low- or high-risk plans with great certainty,
the AUCis a suitable measure of model performanceforclinical data. A ‘good’ model
correctly accounts for all relevant factors influencing the outcome; on the other hand,
even a suboptimal model can be considered validated if the AUC is as high for testing
datasets as for the fitting dataset. The following graphical methods are sometimes used
to demonstrate the validity of a model.
7.4.2 Graphical methods of evaluating model performance
The performance of NT'CP models can be evaluated graphically by binning the data into
groups of similar ¢ and comparing the complication rate in the bins with the NTCP as
a function of ¢. Figures 7.7 and 7.8 show such plots for dataset 1 and 5 for lung, which
resulted in an average AUC of 0.96 and 0.67 respectively. The lower AUCsfor dataset 5,
which included high levels of confounding factors, are reflected by the much shallower
slope of the predicted NTCP curvesin figure 7.8. Note that the ranges of the ¢-axes
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Figure 7.7: Fitted NTCP models compared to the complication rate (CR) in bins of
50 patients with similar EUD orrelative damaged volume,for the first lung dataset
(oq = 0% and orsy = 0%). The fitted models are (a) the LKB model, (b) the relative
seriality model, (c) the 3-parametercritical volume model, and (d) the Vp:, model.
were normalised to the range of ¢-values in the dataset, with constant proportional
margins from the lowest and highest bin values to the frames. This makes it possible to
compare the steepness of the curves, in spite of the different units of the ¢@ axes. There
are twenty bins in each figure, but in some cases the majority are invisible, due to a
complication rate of zero in these bins.
For the four 3-parameter models (LKB,relative seriality, critical volume and Vp;:,)
shown in the figures, NTCPis a function of the equivalent uniform dose (EUDLKp
or EUDrs), or the relative damaged volume. The expression for EUDrs, based on
equation 2.12, depends ontwo of the fitted parameters and the predicted NTCP:
(7.5) EUDps = Dso (1 _ In(@a(1/NTCP)) — an)ey
Figure 7.7 illustrates the difference in model performance when the AUC were 0.93
((a) and (b)) and 0.99 ((c) and (d)). As well as having steeper curves the critical
volume models clearly manage to summarise the dose distributions better, since the
complication rate increases monotonically with the relative damaged volume. This effect
is less apparent in the presence of confoundingfactors (figure 7.8).
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Figure 7.8: Fitted NT'CP models compared to the complication rate (CR) in bins of
50 patients with similar EUDor relative damaged volume,for the fifth lung dataset
(oq = 15% and orsy = 25%). Thefitted models are (a) the LKB model, (b) therelative
seriality model, (c) the 3-parametercritical volume model, and (d) the Vp:p, model.
Figure 7.9 shows another graphical evaluation of the model performance on the two
lung datasets used in this section. Here, the datasets are binned according to their
predicted NTCP, and the NTCP of the bins is compared to the actual complication
rate in the bins. The predictions of a good model should beclose to the y = = line.
Both the previous graphical performance evaluation and the present suffer from
having to consider the average NTCP estimates in data subgroups, since these are
compared to the complication rate which can only be calculated for a group of patients.
Therefore, these methods are not as effective as the AUC where the classification of
every single plan influences the performance measure. With these graphical methods a
model which identified the right fraction of DVHsin each subgroupas high-risk, would
get a good performance estimate, even though the wrong individual plans had been
identified. The AUC,on the other hand, would detect the failure of the modelto classify
individual plans.
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Figure 7.9: Patients binned according to predicted NTCP by the LKB (o), relative
seriality (+), critical volume (x) and Vp, (C1) models, and plotted against the actual
complication rate in the groups (100 patients/group). The dashed line represents y = x.
The datasets are for lung, (a) without confounding factors and (b) with og = 15% and
orsu = 25%, corresponing to dataset 1 and 5 in figure 7.1.
7.4.3 The relative performance of NTCP models
This study shows that the performance of NTCP models is influenced more by con-
founding factors than by the choice of NTCP model. This is in agreement with a
recent study fitting three models to a large dataset of rectal complications following
prostate radiotherapy [195]; all models performed similarly but includingclinical factors
significantly improved the fit. However, two of the models were based on the EUD:
the LKB modeland a logistic model with EUD as summary measure. Thus they were
essentially the same model and the third model, the relative seriality, was shown to
perform very similarly to the LKB model(which is in agreement with the findings in
this chapter). Greater differences in model performance might have been foundif also a
critical volume type model wasincluded in the study.
Theresults in this chapter do not answer the question of which of the DVH-based
models is best. The summary measureof the critical volume model might be expected
to be the most successful one, since it explicitly and transparently takes both dose
and volumeinto account, by estimating the damaged volume based onthe local dose.
However, the performance of an empirical model also depends on how easily it can be
fitted to a dataset, and it has been reported that one of the four parameters of thecritical
volume model cannot be determined with accuracy from clinical datasets [60, 43, 44].
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Also, as shown by van Luijk et al. [60] strong correlations between model parameters
make it difficult to determine confidence intervals for the parameter values.
For the datasets and models considered in this work, best fits could be found,
though in some cases the upper confidence limit for a parameter wasinfinite. On a
practical note, the mean dose model and the 4-parametercritical volume models had
the advantage of easily converging to the same optimal solution, using the maximum
likelihood method,for different starting points in the parameter space. The Vpn model
was quite unstable and the starting point often had to be close to the optimal solution
for the maximumlikelihood methodto find it. This was dealt with by using the more
time consuming simulated annealing approach, as well as a visual inspection of the
full parameter probability distribution. Creating the probability distributions was very
computationally expensive though, and this was usually done by running parts of the
job in parallel on the Condorpool(see section 4.3) at the University of Liverpool.
Interestingly, the LKB modelandtherelative seriality models often performed very
similarly; see discussion in section 2.1.3. However,fitting the relative seriality model to
a dataset took a lot longer than fitting the LKB model.
7.4.4 The influence of confounding factors
In this work only three selected variables which were knownto influence the outcome
(¢, w and N&SU) were included, when modelling also non-dosimetric factors. This is
in contrast to the approach by the Washington University group, which is based on
an automated variable selection which allows models built from several dose-volume
parameters as well as patient-specific variables [100]. With their approach the dataset is
heavily relied on for inference as well as parameterfitting; no a priori understanding of
the cause andeffect of the complication of interest is taken into account in the variable
selection. Thus the resulting models are optimised for the characteristics of the fitting
dataset but it is likely that the specific combination of dose-volumevariable selected by
this method would bedifferent for other datasets.
This leads to the question whether a good modelshould yield high AUC values for
all datasets; depending on the interpatient variablility in dosimetric and non-dosimetric
variables, these variables are not of the same relative importance for a predictive model
applied to different datasets. The fact that the most important predictive variables for
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a given endpoint differ between different studies could be explained by somevariables
being effectively constant from patient to patient in one dataset, whilst varying in
another. Or, as observed by Dehing-Oberije et al. [148], dosimetric variables seem to
be more important for datasets including treatments of high mean lung dose than for
datasets with only low mean lung doses.
However, as shown by the results in section 7.3.4, correctly accounting for the
most important predictive variables (nondosimetric in dataset 5) results in a high
AUC,irrespective of how well(/poorly) less important variables are accounted for
(e.g. maximum dose in dataset 5). The interpatient variability in dosimetric and
non-dosimetric variables are likely to differ between datasets from different centres and
years of treatment, and a general predictive model could be built by identifying, and
quantifying the influence of, such variables from the datasets where a large variability
exists. Thus, the general model might include a large numberofvariables, but only
some of them might be relevant for a given dataset. The AUC would behighonly if at
least all the relevant variables were selected into the model.
Figure 7.1 showed that for lung the relative importance of og and orsy was
comparable. For the rectum datasets on the other hand, figure 7.2 showed that the
performanceof all models was influenced more by og than by orgy. The reason for this
is not clear, but could be related to the smaller volume effect of the rectum compared
to the lung; organs with a small functional reserve are especially vulnerable to severe
local tissue damage, whether due to excessive dose or high radiosensitivity. However, it
might also reflect characteristics in the dataset.
7.5 Conclusions
The results in this chapter indicate that the influence of confounding factors on the
performance of NTCP modelsis greater than the choice of model. The great improvement
in the performance of the models when relevant non-dosimetric factors were included,
motivates efforts to find methods to identify and quantify such factors.
Once relevant patient-specific factors are known and can beincluded in the NTCP
models, critical volume models could prove to be superior to other DVH-based NTCP
models for lung. However, efforts should first be made to account for confoundingfactors.
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The most efficient way to account for non-dosimetric variables is to include them as
covariates alongside a (DVH) summary measurein a logit function- or probit function
based model.
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Table 7.1: Maximum likelihood estimates of the parameter values for fits of NT'CP
models to pseudo-clinical lung data presented in figure 7.1. See text for definitions of
parameters.
 
 
 
 
 
$50/Ds0 m/y n/s/Dso k
dataset 1: gg = 0%, orsy = 0%
LKB 12.5 Gy 0.136 3.01
Mean dose 20.6 Gy 0.112
Maximum dose 638 Gy 0.869
Relative seriality 21.1 Gy 2.71 7.78 x 10-4
Critical volume (4p) 0.465 0.0305 13.6 Gy 10.3
Critical volume (3p) 0.507 0.0313 15.1 Gy
Voth 0.478 0.0429 14.1 Gy
dataset 2: og = 15%, orsy = 0%
LKB 15.8 Gy 0.261 1.61
Mean dose 20.3 Gy 0.230
Maximum dose 115 Gy 0.663
Relative seriality 20.1 Gy 160 40x10
Critical volume (4p) 0.464 0.189 13.3 Gy 6.79
Critical volume (3p) 0.531 0.182 13.9 Gy
Voth 0.476 0.243 14.0 Gy
dataset 3: og = 0%, orsy = 15%
LKB 13.2 Gy 0.320 2.50
Mean dose 20.6 Gy 0.271
Maximum dose 413 Gy 1.36
Relative seriality 20.7 Gy 1.29 9.42 x 10-5
Critical volume (4p) 0.459 0.254 14.4 Gy 31.9
Critical volume (3p) 0.573 0.435 13.8 Gy
Voth 0.459 0.256 14.7 Gy
dataset 4: a5 = 0%, orsy = 25%
LKB 12.4 Gy 0.555 2.69
Mean dose 19.9 Gy 0.471
Maximum dose 280 Gy 2.31
Relative seriality 19.9 Gy 0.800 5.15 x 10-5
Critical volume (4p) 0.505 0.304 11.5 Gy 58.9
Critical volume (3p) 0.473 0.354 15.6 Gy
Voth 0.422 0.470 15.3 Gy
dataset 5: gg = 15%, orsy = 25%
LKB 13.2 Gy 0.562 2.34
Mean dose 20.1 Gy 0.481
Maximum dose 281 Gy 2.22
Relative seriality 20.2 Gy 0.787 8.04 10°
Critical volume (4p) 0.427 0.446 15.0 Gy 46.4
Critical volume (3p) 0.434 0.449 14.9 Gy
Voth 0.427 0.387 16.6 Gy
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Table 7.2: Maximum likelihood estimates of the parameter values for fits of NT'CP
models to pseudo-clinical rectum data presented in figure 7.2. See text for definitions of
parameters.
 
 
 
 
 
$50/D350 m/y
—
n/s/Ds0 k
dataset 1: gg = 0%, orsy = 0%
LKB 46.4 Gy 0.0433 0.466
Mean dose 38.7 Gy 0.0651
Maximum dose 78.7 Gy 0.0683
Relative seriality 40.2 Gy 8.20 2.96 x 107°
Critical volume (4p) 0.458 0.0770 34.7 Gy 8.84
Critical volume (3p) 0.535 0.0564 35.6 Gy
Voth 0.481 0.115 34.6 Gy
dataset 2: gg = 0%, orsu = 10%
LKB 51.8 Gy 0.0607 0.293
Mean dose 38.6 Gy 0.109
Maximum dose 76.4 Gy 0.0606
Relative seriality 42.4 Gy 4.53 8.51 «x 107%
Critical volume (4p) 0.456 0.161 34.8 Gy 8.91
Critical volume (3p) 0.524 0.122 36.2 Gy
Voth 0.538 0.224 31.0 Gy
dataset 3: gg = 10%, orsu = 0%
LKB 50.8 Gy 0.0974 0.335
Mean dose 39.3 Gy 0.152
Maximum dose 77.7 Gy 0.0833
Relative seriality 43.7 Gy 3.36 0.0370
Critical volume (4p) 0.462 0.221 35.5 Gy 8.16
Critical volume (3p) 0.548 0.172 35.4 Gy
Voth 0.548 0.283 31.1 Gy
dataset 4: a, = 15%, orsu = 0%
LKB 48.7 Gy 0.134 0.391
Mean dose 39.0 Gy 0.391
Maximum dose 78.6 Gy 0.113
Relative seriality 43.2 Gy 2.75 0.0686
Critical volume (4p) 0.475 0.266 33.3 Gy 9.53
Critical volume (3p) 0.545 0.210 35.0 Gy
Voth 0.528 0.323 31.1 Gy
dataset 5: og = 15%, orsy = 10%
LKB 50.5 Gy 0.152 0.341
Mean dose 39.0 Gy 0.220
Maximum dose 78.0 Gy 0.118
Relative seriality 45.9 Gy 2.51 0.165
Critical volume (4p) 0.443 0.336 36.4 Gy 10.1
Critical volume (3p) 0.522 0.264 37.3 Gy
Voth 0.340 0.393 62.5 Gy
118
Table 7.3: AUC of the LKB modelfitted to subsets of lung dataset 5, stratified according
to radiosensitivity (w) and health status, represented by the initial FSU density (N4’SY).
The complication rate in each subset is given in brackets. The values of a and Ne_
are the middle values of the bins. The AUCfor the total dataset was 0.65, and for the
corresponding dataset without confounding factors 0.93.
 a = 0.19 a = 0.23 a = 0.25 a = 0.33
N&SY = 2200 0.61 (25/62) 0.82 (40/62) 0.83 (59/62) - (62/62)
N&S¥ = 3300 1.0 (1/62) 0.74 (19/62) 0.80 (36/62) 0.94 (54/62)
Nee" = 3900. - (0/62) 0.61 (3/62) 0.95 (13/62) 0.79 (32/62)
Nee? 5800 = (0/62) - (0/62) 1.0 (1/62) 0.90 (13/62)
Table 7.4: AUC of the 3-parameter critical volume modelfitted to subsets of lung
dataset 5, stratified according to radiosensitivity (a) and health status, represented
by the initial FSU density (Né’S”). The complication rate in each subset is given in
brackets. The values of a and Né’SY are the middle values of the bins. The AUC for the
total dataset was 0.69, and for the corresponding dataset without confounding factors
0.99.
 a = 0.19 a = 0.23 a = 0.25 a= 0.33
N&S¥ = 2200 0.77 (25/62) 0.84 (40/62) 0.95 (59/62) - (62/62)
N&S¥ = 3300 1.0 (1/62) 0.92 (19/62) 0.97 (36/62) 0.96 (54/62)
Nee? = 3900 - (0/62) 0.90 (3/62) 0.95 (13/62) 0.79 (32/62)
Ng?" = 9800 - (0/62) - (0/62) 1.0 (1/62) 0.91 (13/62)
Table 7.5: AUC of the LKB model fitted to subsets of rectum dataset 5, stratified
according to radiosensitivity (a) and health status, represented by the initial FSU
density (Nf5Y). The complication rate in each subset is given in brackets. The values
of a and N¢'SY are the middle values of the bins. The AUCfor the total dataset was
0.76, and for the corresponding dataset without confounding factors 0.97.
 a=0.0388 a=0.048 a=0.052 a=0.070
N&SY = 310 - (0/62) 0.93 (9/62) 0.86 (33/62) 0.91 (43/62)
N&’SY = 360 - (0/62) 0.92 (3/62) 0.88 (13/62) 0.97 (36/62)
N&’s¥ = 380 - (0/62) - (0/62) 0.91 (7/62) 0.93 (33/62)
NASY = 450° =~ (0/62) 0.98 (2/62) 0.98 (2/62)... 0.82 (12/62)
Table 7.6: AUC of the 3-parametercritical volume model fitted to subsets of rectum
dataset 5, stratified according to radiosensitivity (a) and health status, represented
by the initial FSU density (NeSU) The complication rate in each subset is given in
brackets. The values of a and Né’SY are the middle values of the bins. The AUC for the
total dataset was 0.76, and for the corresponding dataset without confounding factors
0.98.
 a=0.0388 a=0.048 a=0.052 a=0.070
NS" =310 - (0/62) 0.95 (9/62) 0.93 (33/62) 0.90 (43/62)
Nae" = 360 ~~ (0/62) 1.0 (8/62) 0.94 (13/62) 0.9% (36/62)
NeSU = 380 - (0/62) - (0/62) 0.92 (7/62) 0.93 (33/62)
Nee" = 20 --(0/62). 10(2/62) 1.02/62)  @3i (12/62)
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Table 7.7: Maximum likelihood estimates of the parameter values for fits of NTCP
models including confounding factors to pseudo-clinical lung dataset 5.
 
 
Bo py Ba DG n/Ds0 k
Logit model
LKB -12.1 0.830 93.0: =57:8 2:75
Mean dose -13.6 0.581 90.0 -55.6
Maximum dose -2.71 -0.0140 66.2 -38.6
Critical volume (4p) -30.2 54.8 159 -99.1 12.3 14.0
Critical volume (3p) -24.3 44.4 134 -83.3 15.4
Voth -22.5 41.9 148 -91.2 14.1
Probit model
LKB 14.0 0.156 49.7 -31.7 2.69
Mean dose -7.28 0.325 48.2 -30.5
Maximum dose -1.38 -0.00869 35.9 -21.0
Critical volume (4p) 0.518 0.0697 76.1 -49.3 12.5 12.0
Critical volume (3p) 0.534 0.0682 77.3 -49.9 14.9
Voth 0.501 0.0903 72.9 -46.9 14.0
Table 7.8: Maximumlikelihood estimates of the parameter values for fits of NTCP
models including confounding factors to pseudo-clinical rectum dataset 5.
 
 
Bo Ai Bo 63 n/Deo k
Logit model
LKB -54.6 0.855 690 -642 0.315
Mean dose -30.5 0.586 535 -516
Maximum dose -33.0 0.373 330 -338
Critical volume (4p) -28.0 41.1 680 -649 36.2 12.7
Critical volume (3p) -27.7 45.4 655 -593 64.4
Vpth -24.9 34.5 643 -633 35
Probit model
LKB 63.0 0.0346 354 -327 0.324
Mean dose -16.9 0.322 286 -267
Maximum dose =18.1,.°°0:203 107 ..-170
Critical volume (4p) 0.699 0.0669 341 -310 36.3 12.4
Critical volume (3p) 0.751 0.0535 351 -318 36.9
Voth 0.749 0.0760 318 -295 35.0
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Chapter 8
Conclusions
8.1 The 3D model of normal tissue response
This thesis has introduced a novel methodof exploring the interface between theoretical
radiobiology andclinical radiotherapy; a mechanistic 3D computer model of normal-
tissue response to irradiation was developed, which simulates pseudo-clinical outcome
data for arbitrary dose distributions.
The model is unavoidably simplistic, with local tissue damage represented by FSU
inactivation, and the volumeeffect (determining organ injury) represented by critical
functioning volume (CFV). Whilst the local dose effect was assumed to bea result of
cell kill, and given by the LQ model and binomialstatistics, the specific mechanisms of
loss of organ function, resulting from a 3D distribution of inactivated FSUs, were not
specified. Instead, the very general concept of the CFV was allowed to represent all
factors influencing the volumeeffect. In chapter 6 it was found that these mechanismsare
different for different organs, which determinedthesize of the CFV and the organ-specific
threshold of FSU inactivation within the CFV for causing a complication.
Chapter 6 was devotedto tailoring the parameter values of the model to as closely as
possible represent lung and rectum as organsat risk, based on data from the literature.
It was concluded that the alveolus of the lung has the appropriate numberofepithelial
stem cells to function as the FSU for the endpoint of radiation pneumonitis, and that
the capillary cluster around a mucosal gland in the rectum is plausible as the FSU for
the endpoint of late rectal bleeding. As expected, the lung was found to have a large
volume effect, which to some extent depends on inflammatory processes triggered by
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radiation-induced tissue damage. In contrast, there is no consensus about the volume
effect of the rectum, but an intermediate size of the CFV seemed appropriate.
Whenthe radiobiological knowledgebase of normal-tissue damage had been inves-
tigated, it was concluded that more quantitative data on local tissue damage, over
a large dose range, would greatly enhance the potential for mechanistic modelling of
normal-tissue complications. Determining the local tissue dose-response separately
would provide a stepping stone from which the mechanismsof organ function loss, as a
result of 3D distributions of FSU inactivation, could be studied. However, for many
organs and endpoints the most relevant measure of local tissue function has yet to be
determined.
Unlike DVH-based NTCP models, the developed 3D model can include spatial
effects of dose distributions, and rather than to evaluate treatment plans its purpose
is to simulate radiotherapy treatments, generating pseudo-clinical complication data
for a patient depending on the choice of a set of parameters. Such simulations are
ideal for studying data-analysis methodology, given the flexibility of the model and that
simulations are easily performed in large numbers. However, becauseof the relative
complexity of the model, simulations were computationally expensive, and the studies
in this thesis were only feasible by running the simulations on a cluster of computers
(see section 4.3).
8.2 Conclusions from studies on simulated data
The 3D model developed in this thesis was described in chapter 4, and in chapter 5
the model was used to generate pseudo-clinical data for a correlation analysis. Here
three different generic organ types (parallel, semi-parallel and serial) were simulated by
choosing different values for the CFV. Once the data had beengenerated, a correlation
analysis between outcome and manydifferent dosimetric parameters wascarried out,
and the results were linked to characteristics of the sets of dose distributions in the
analysis.
It was found that the responseof the parallel and serial organs was strongly dependent
on the mean and maximum organdoserespectively, whilst no parameter related strongly
to the outcome for the semi-parallel organ. In the former case all Vz and Dz; parameters
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correlating strongly with the outcome could be explained by a cross-correlation with
the mean or maximum dose respectively. The inter-patient variability in dosimetric
parameters was also shown to influence the strength of correlation observed. However,
it was found that the volume, z, for which the D, parameter correlated the strongest
with outcomefor the serial and semi-parallel organs, corresponded to thesize of the
CFV. This indicates that some information of the volumeeffect of an organ can be
gained from correlation analysis, if care is taken to identify other factors influencing
the observed correlations.
After having derived plausible values for the 3D model parameters in chapter 6, in
order to represent two real organs, in chapter 7 simulations were carried out for radiation
pneumonitis and late rectal bleeding as endpoints, with dose distributions representative
of lung and prostate cancer treatments. Various DVH-based NTCP models were then
fitted to the generated pseudo-clinical datasets. These datasets included different levels
of confounding factors (inter-patient variation in both radiosensitivity and health status),
which allowed the performance of the models to be compared undervarious conditions.
The results showed that the influence of confounding factors on the performance of
DVH-based models is more important than the choice of model. Further, methodologies
for accounting for non-dosimetric factors were described, and the importance of finding
ways of quantifying such factors was emphasised.
8.3 Future work
Since the studies in chapters 5 and 7 were intendedto exploreeffects influencing analyses
of clinical data, the datasets generated for these studies were made to resemble clinical
datasets, in terms of inter-patient variation in doses and volumes treated. Typically, each
patient had a unique, automatically generated, dose distribution, and in some datasets
each patient also had a unique value of a and N&SU (sampled from a lognormal /
log-lognormal distribution respectively), representing radiosensitivity and health status.
Consequently, the data simulated and analysed in this thesis were characterised
largely by the dose distributions. However, due to its structure the model lendsitself
to explore several other phenomena important to radiotherapy; future applications of
the model could include initially inhomogeneous FSU distributions, representing e.g.
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the spatial distribution of organ damage detected by functional imaging, as well as
modifications to the cell kill function to include low-dose hypersensitivity and time-
effects. It would also be of special interest to introduce non-local effects of irradiation
into the model(i.e. radiation-induced bystandereffects; see e.g. [196]), such that the
cell kill is determined not only by the local dose, but also by the dose to cells in the
vicinity.
Just as the performance of DVH-based NTCP models wastested on data simulated by
the model, so that the fitted model parameters could be comparedto the ‘actual’ volume
effect and local dose-response function (chapter 7), also the feasibility of retrieving
the a/-ratio of the LQ-model from ‘clinical’ datasets of different fractionation could
be tested. Focusing further on fractionation, it would also be of interest to generate
Strandqvist isotoxicity curves for different sizes of the CFV, and test different models’
ability to predict the results.
The 3D model will further be adapted to be able to simulate treatments based on
actual treatment plans. The full dose cubes and structure information for prostate
treatments could be imported into the model, and rather than defining the rectum
as a square tube, as in chapter 6, the outline of the real rectum would be used. In
this way the plausibility of the model parameters derived for rectum could be tested
further. Also, different endpoints relevant for one and the sameorgan,like late rectal
bleeding and loose stools, can be modelled simultaneously by applying the same dose
distribution to two different FSU distributions which co-exist in the same voxels. The
size of the CFV is expected to be different for these different endpoints, as well as the
dose response of the FSU populations.
It might be convenient to adapt the model code to be able to run simulations
in parallel on a GPU,rather than on a dedicated cluster of computers. This would
potentially greatly simplify the logistics of using the model.
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